Compugen Overview
Compugen is a clinical-stage drug-discovery and development company with a broadly applicable predictive-discovery infrastructure that is advancing a therapeutic pipeline consisting mainly of early-stage immuno-oncology programs aimed at harnessing the immune system to eradicate cancer. The company's pipeline is based on novel Compugen-discovered drug targets, primarily immune checkpoint candidates that are predicted to provide cancer immunotherapies addressing unmet cancer types and patient populations, both as monotherapies and in combination. In 2010, Compugen chose to specialize in oncology and immunology, with a focus on immuno-oncology. Compugen's first application of its predictive discovery infrastructure was in the field of immune checkpoints, with the goal of developing novel, effective cancer immunotherapies. The company has also expanded its discovery capabilities to include myeloid target candidates within the tumor microenvironment. Today, Compugen's pipeline includes multiple opportunities for therapeutics addressing areas of unmet medical need in the field of oncology.
Cumulative Funding Raised Over Time ($)
$30.0MJan 2013
$34.9MJul 2007
$54.9MNov 2021
$66.9MOct 2018
Latest News
growth-positive
Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025
Compugen Ltd., a clinical-stage cancer immunotherapy company, is set to release its third quarter 2025 financial results on November 10, 2025. The company specializes in predictive computational drug target discovery powered by AI/ML. Compugen has several product candidates in various stages of clinical development, including COM701 and COM902, which are in Phase 1, and a bispecific antibody in Phase 3 development through a partnership with AstraZeneca. Additionally, GS-0321 is in Phase 1 development under a license agreement with Gilead. The company is headquartered in Israel and has offices in San Francisco, CA.
Product StagePartners
growth-positive
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target...
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced a pooled analysis supporting the anti-tumor activity and safety profile of COM701 in patients with platinum-resistant ovarian cancer. The analysis, presented at the European Society of Medical Oncology (ESMO), supports the rationale for evaluating COM701 as maintenance therapy in earlier treatment lines. Compugen is conducting the MAIA-ovarian trial to assess COM701 monotherapy in relapsed platinum-sensitive ovarian cancer. The company expects interim analysis results by the end of 2026. Compugens partner, AstraZeneca, will present related research at ESMO. The company utilizes AI/ML-powered computational discovery for developing cancer immunotherapies. Compugens cash reserves are expected to support operations into 2027.
Product StagePartners
growth-positive
Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced a pooled analysis of data supporting the anti-tumor activity and safety profile of COM701 in patients with platinum-resistant ovarian cancer. The analysis, published by the European Society of Medical Oncology (ESMO), focuses on 60 evaluable patients from prior Phase 1 clinical trials. The results suggest that COM701 is well-tolerated and shows durable responses, particularly in patients with lower disease burden. This supports the rationale for evaluating COM701 as maintenance therapy in earlier treatment lines. Compugen is conducting the MAIA-ovarian trial to assess COM701 monotherapy in relapsed platinum-sensitive ovarian cancer.
Product StageFDA approved/pending approval
growth-positive
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target...
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced the progress of its first-in-human clinical trial for the anti-IL18BP antibody, COM503 (GS-0321), targeting advanced solid malignancies. The trial will be presented at the Society for Immunotherapy of Cancers Annual Meeting in November 2025. Compugen utilizes AI/ML-powered computational discovery to identify new drug targets and pathways for cancer immunotherapies. The company has multiple product candidates in development, including COM701 and COM902, and has licensed GS-0321 to Gilead. Compugen collaborates with AstraZeneca for the development of bispecific antibodies. The company is headquartered in Israel and listed on Nasdaq and the Tel Aviv Stock Exchange.
Product StagePartners
growth-positive
Compugen to Present at SITC 2025
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced the progress of its first-in-human clinical trial for the anti-IL18BP antibody, COM503 (GS-0321), targeting advanced solid malignancies. The trial will be presented at the Society for Immunotherapy of Cancers 40th Annual Meeting in November 2025. Compugen utilizes AI/ML-powered computational discovery to identify new drug targets and pathways for cancer immunotherapies. The company has multiple product candidates in development, including COM701 and COM902, with partnerships such as a license agreement with AstraZeneca for a bispecific antibody in Phase 3 development. Compugens GS-0321 is licensed to Gilead. The company is listed on Nasdaq and the Tel Aviv Stock Exchange.
Product StagePartners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $141.92M |
| Last funding | $20M |
| Stage | Public |
| Rounds | 7 |
| Investors | 3 |
Team Members
5
Employees: 51-200
Web & Social Links
| Website | www.cgen.com |
| Careers | Careers page |
Locations
Harokmim 26, Holon, Israel
395 Oyster Point Boulevard, South San Francisco, CA, USA
Photos & Videos
1 item(s)
Compugen Business
Business models
B2B
Product stage
Clinical Trial
Employees
51-200
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentDrug DeliveryTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcarePatientsCore Technology
BiologicalsTags (14)
immunologyoncologybiotechnologybioinformaticsantibodiesdrug-discoveryproteinspharmaceuticalsimmunotherapycancer-therapyautoimmune-diseasespatientspharma-companiescancerGeographic Markets
IsraelUnited StatesCanadaCompugen Financials
$141.92M
Total funding
Undisclosed
Capital raised
$20M
Last funding
Public
Funding stage
7
Total rounds
3
Investors
Cumulative Funding Raised Over Time ($)
$30.0MJan 2013
$34.9MJul 2007
$54.9MNov 2021
$66.9MOct 2018
Private Equity Funding
PIPE
Nov 2021
$20M
Bristol-Myers Squibb Company
PIPE
Oct 2018
$12M
Bristol-Myers Squibb Company
PIPE
Jan 2013
$30M
GlobalServe, Bayer HealthCare
PIPE
Jul 2007
$4.92M
GlobalServe
Public Offering / Exit
POEvent
Mar 2020
Undisclosed
POEvent
Jan 2002
Undisclosed
POEvent
Aug 2000
Undisclosed
Compugen Lifecycle
Cumulative Funding Raised Over Time
$30.0MJan 2013
$34.9MJul 2007
$54.9MNov 2021
$66.9MOct 2018
All Events
PIPE
Nov 2021
$20M
Bristol-Myers Squibb Company
PIPE
Oct 2018
$12M
Bristol-Myers Squibb Company
PIPE
Jan 2013
$30M
GlobalServe, Bayer HealthCare
PIPE
Jul 2007
$4.92M
GlobalServe
POEvent
Mar 2020
Undisclosed
POEvent
Jan 2002
Undisclosed
POEvent
Aug 2000
Undisclosed
Compugen News
198 articles
growth-positive
Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025
Compugen Ltd., a clinical-stage cancer immunotherapy company, is set to release its third quarter 2025 financial results on November 10, 2025. The company specializes in predictive computational drug target discovery powered by AI/ML. Compugen has several product candidates in various stages of clinical development, including COM701 and COM902, which are in Phase 1, and a bispecific antibody in Phase 3 development through a partnership with AstraZeneca. Additionally, GS-0321 is in Phase 1 development under a license agreement with Gilead. The company is headquartered in Israel and has offices in San Francisco, CA.
Product StagePartners
growth-positive
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target...
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced a pooled analysis supporting the anti-tumor activity and safety profile of COM701 in patients with platinum-resistant ovarian cancer. The analysis, presented at the European Society of Medical Oncology (ESMO), supports the rationale for evaluating COM701 as maintenance therapy in earlier treatment lines. Compugen is conducting the MAIA-ovarian trial to assess COM701 monotherapy in relapsed platinum-sensitive ovarian cancer. The company expects interim analysis results by the end of 2026. Compugens partner, AstraZeneca, will present related research at ESMO. The company utilizes AI/ML-powered computational discovery for developing cancer immunotherapies. Compugens cash reserves are expected to support operations into 2027.
Product StagePartners
growth-positive
Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced a pooled analysis of data supporting the anti-tumor activity and safety profile of COM701 in patients with platinum-resistant ovarian cancer. The analysis, published by the European Society of Medical Oncology (ESMO), focuses on 60 evaluable patients from prior Phase 1 clinical trials. The results suggest that COM701 is well-tolerated and shows durable responses, particularly in patients with lower disease burden. This supports the rationale for evaluating COM701 as maintenance therapy in earlier treatment lines. Compugen is conducting the MAIA-ovarian trial to assess COM701 monotherapy in relapsed platinum-sensitive ovarian cancer.
Product StageFDA approved/pending approval
growth-positive
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target...
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced the progress of its first-in-human clinical trial for the anti-IL18BP antibody, COM503 (GS-0321), targeting advanced solid malignancies. The trial will be presented at the Society for Immunotherapy of Cancers Annual Meeting in November 2025. Compugen utilizes AI/ML-powered computational discovery to identify new drug targets and pathways for cancer immunotherapies. The company has multiple product candidates in development, including COM701 and COM902, and has licensed GS-0321 to Gilead. Compugen collaborates with AstraZeneca for the development of bispecific antibodies. The company is headquartered in Israel and listed on Nasdaq and the Tel Aviv Stock Exchange.
Product StagePartners
growth-positive
Compugen to Present at SITC 2025
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced the progress of its first-in-human clinical trial for the anti-IL18BP antibody, COM503 (GS-0321), targeting advanced solid malignancies. The trial will be presented at the Society for Immunotherapy of Cancers 40th Annual Meeting in November 2025. Compugen utilizes AI/ML-powered computational discovery to identify new drug targets and pathways for cancer immunotherapies. The company has multiple product candidates in development, including COM701 and COM902, with partnerships such as a license agreement with AstraZeneca for a bispecific antibody in Phase 3 development. Compugens GS-0321 is licensed to Gilead. The company is listed on Nasdaq and the Tel Aviv Stock Exchange.
Product StagePartners
growth-positive
Q3 Virtual Investor Summit: On-Demand Presentations Now Available
SuperCom Ltd., a technology company, has experienced significant growth since mid-2024 by securing over 30 new contracts across the USA and forming 9 new partnerships with regional service providers. This expansion includes entry into 11 new states, indicating a strong growth trajectory. The company is poised to continue its expansion and capitalize on new market opportunities. The article highlights the companys strategic partnerships and contract acquisitions as key drivers of its recent success.
Partners
growth-positive
Presenting at the Investor Summit Q3 2025 on September 16; Watch the Live Stream for Free
The Investor Summit Group is hosting its Q3 Investor Summit Virtual on September 16, 2025. This event is designed to enhance visibility for issuers and efficiency for investors by showcasing companies with strong leadership and innovative products. The summit serves as a platform for connecting quality companies with serious investors. The event features a schedule of presentations from various companies across different sectors, providing an opportunity for these companies to present their growth strategies and innovations to potential investors. The summit is a significant opportunity for companies to gain exposure and for investors to discover promising investment opportunities.
growth-positive
Nikkiso Addresses Growing Ammonia-Handling Demand and Launches Next-Generation Pump at Gastech 2025
Nikkiso Clean Energy & Industrial Gases Group (Nikkiso CE&IG) announced the launch of a next-generation submerged ammonia pump at the Gastech Conference. This pump is designed to be the safest and most reliable in the industry, addressing common maintenance issues with its seal-less, maintenance-friendly, copper-free construction. The pump can deliver over 2,500m3 per hour and has a mean time between outages of over 16,000 hours. This launch is part of Nikkiso CE&IGs ongoing innovation in ammonia handling, with the company having decades of experience in this field. The pump is expected to meet growing demand for ammonia in various sectors, including power generation and shipping.
Product Stage
growth-positive
BHP Xplor Opens Applications for 2026 Cohort, Offering Equity-Free Funding and Global Support
BHP Group Limited has announced the opening of applications for the 2026 cohort of its BHP Xplor accelerator program, which aims to transform the discovery of critical minerals. The program offers early-stage explorers up to USD $500,000 in equity-free funding, mentorship, and access to BHP’s global network. BHP Xplor has been successful in previous years, fostering partnerships and accelerating exploration projects. The program supports BHPs long-term growth by engaging with diverse exploration projects. Applications are open from September 8 to October 15, 2025.
Partners
growth-positive
Westin Desaru Coast Resort partners with CAYIN Technology for digital signage
CAYIN Technology has partnered with Westin Desaru Coast Resort in Johor, Malaysia, to enhance guest communication and operational efficiency through the implementation of its CMS-WS server and CAYIN Signage Player. This collaboration involves the use of digital signage to provide real-time updates across 14 Samsung displays in various areas of the resort. The project was executed in partnership with Hola Media, which provided integration services, including installation, design, staff training, and support. The system has improved communication, reduced staff workload, and enhanced the guest experience, preparing the resort for future digital expansion.
Partners
growth-positive
Assessing the Valuation of Yue Yuen Industrial (SEHK:551) After Recent Volatility
Yue Yuen Industrial (Holdings) has experienced notable stock price fluctuations, drawing attention from investors. Despite a year-to-date decline of 21%, the company has shown resilience with an 11% gain over the past year and a 13% increase in the past three months. Over a longer period, the stock is up 53% over three years and 44% over five years. The companys P/E ratio of 7.2x suggests it is undervalued compared to industry peers, indicating potential for growth if profit levels are sustained or improved. While the company shows steady revenue and net income growth, risks remain due to inconsistent short-term returns and potential shifts in market sentiment.
growth-positive
Nifty clocks fifth session of gains led by IT on Infosys buyback, US rate cut hopes
Infosys led gains in Indias Nifty 50 index, which closed higher for the fifth consecutive session, driven by a 5% surge in Infosys shares following the announcement of a share buyback plan. The IT sector, which accounted for a significant portion of the days gains, benefited from expectations of a U.S. interest rate cut, which could boost technology spending in the U.S., a key market for Indian IT firms. The broader market also saw gains, with the Nifty 50 and BSE Sensex both rising by 0.39%. The anticipation of a Federal Reserve rate cut was fueled by weaker-than-expected U.S. job data.
growth-positive
Compugen to Present Research at the Single Cell Genomics 2025 Conference
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced its participation in the Single Cell Genomics 2025 Conference in Stockholm, Sweden. The company will present its research on spatial transcriptomics, which may enhance drug discovery and therapeutic strategies for cancer patients. Compugen utilizes AI/ML-powered computational discovery to identify new drug targets and pathways. It has two proprietary product candidates in Phase 1 development and a bispecific antibody in Phase 3 development through a partnership with AstraZeneca. Additionally, a product candidate is licensed to Gilead. Compugen is headquartered in Israel and listed on Nasdaq and the Tel Aviv Stock Exchange.
Product StagePartners
growth-positive
Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced its participation in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference. The company utilizes AI/ML-powered computational discovery platforms to identify new drug targets and biological pathways for cancer immunotherapies. Compugen has proprietary product candidates in Phase 1 development, including COM701 and COM902, with a Phase 3 development product, Rilvegostomig, licensed to AstraZeneca. Another product, GS-0321, is licensed to Gilead. The companys therapeutic pipeline aims to activate the immune system against cancer. Compugen is headquartered in Israel and has offices in San Francisco, CA, with shares listed on Nasdaq and the Tel Aviv Stock Exchange.
Product StagePartners
growth-negative
Need To Know: Analysts Just Made A Substantial Cut To Their Compugen Ltd. (NASDAQ:CGEN) Estimates
Compugen Ltd. (NASDAQ:CGEN) is facing a negative outlook as analysts have significantly revised their forecasts for the company, cutting both revenue and earnings per share (EPS) estimates. The revised forecast predicts a 71% decline in sales by 2025, with per-share losses expected to increase to US$0.34. Despite these downgrades, analysts have raised the price target by 14% to US$6.25, suggesting that the lower EPS may not impact the stocks long-term value. However, Compugens expected revenue decline contrasts sharply with the 19% annual growth forecast for its industry peers, indicating that the company may underperform compared to the wider market.
growth-positive
Compugen Reports Second Quarter 2025 Results
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced the dosing of the first patient in its MAIA-ovarian platform trial for COM701 maintenance therapy in platinum-sensitive ovarian cancer. The company is also progressing with a Phase 1 trial for GS-0321, an anti-IL18BP antibody licensed to Gilead. Partner AstraZeneca is advancing its rilvegostomig program, which includes ten active Phase 3 trials. Compugen is poised for potential revenue from milestone payments and royalties from AstraZenecas developments. The company maintains a solid financial position with a cash runway expected to fund operations into 2027.
Product StagePartners
growth-negative
Compugen (CGEN) Reports Q2 Loss, Lags Revenue Estimates
Compugen reported a quarterly loss of $0.08 per share, missing the Zacks Consensus Estimate of a $0.07 loss. This marks a 14.29% earnings surprise. The company also reported revenues of $1.26 million, significantly below the expected $5.29 million, marking a 76.15% miss. Over the last four quarters, Compugen has consistently failed to meet consensus EPS and revenue estimates. The companys shares have declined by 4.6% year-to-date, underperforming the S&P 500s 7.1% gain. The earnings outlook remains uncertain, with a Zacks Rank #3 (Hold), indicating expected market performance in the near term. Future stock movements will depend on managements commentary and earnings estimate revisions.
growth-negative
Compugen: Q2 Earnings Snapshot
Compugen Ltd., a drug developer based in Holon, Israel, reported a loss of $7.3 million in its second quarter, translating to a loss of 8 cents per share. This result fell short of Wall Street expectations, where analysts anticipated a loss of 7 cents per share. Additionally, the company posted revenue of $1.3 million, which did not meet the forecasted $5.3 million by analysts. The financial results indicate a growth-negative impact on the company as it struggles to meet market expectations.
growth-positive
Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced it will present a pooled analysis of data from three Phase 1 trials evaluating COM701 in ovarian cancer patients at ESMO 2025. The company is utilizing its AI/ML-powered computational discovery platform to identify new drug targets for cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701 and COM902. Additionally, AstraZeneca is developing a bispecific antibody derived from Compugens COM902, and Gilead has licensed a Phase 1 anti-IL-18 binding protein antibody from Compugen. The company is headquartered in Israel and listed on Nasdaq and the Tel Aviv Stock Exchange.
Product StagePartners
growth-positive
Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced it will release its second quarter 2025 financial results on August 6, 2025. The company utilizes AI/ML-powered computational discovery to identify new drug targets for cancer immunotherapies. It has two proprietary product candidates in Phase 1 development and a PD-1/TIGIT bispecific antibody in Phase 3 development through a partnership with AstraZeneca. Additionally, a high-affinity anti-IL-18 binding protein antibody is in Phase 1 development, licensed to Gilead. Compugen is headquartered in Israel and listed on Nasdaq and the Tel Aviv Stock Exchange.
Product StagePartners
growth-positive
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target...
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced it will release its second quarter 2025 financial results on August 6, 2025. The company utilizes a predictive AI/ML-powered computational discovery platform to identify new drug targets for cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development and a bispecific antibody in Phase 3 development through a partnership with AstraZeneca. Additionally, a potential first-in-class antibody is licensed to Gilead. The company is headquartered in Israel and listed on Nasdaq and the Tel Aviv Stock Exchange.
Product StagePartners
growth-positive
Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced the dosing of the first patient in a global randomized sub-trial of its MAIA-ovarian trial. This trial evaluates COM701, an anti-PVRIG antibody, as a maintenance therapy for relapsed platinum-sensitive ovarian cancer. The trial is supported by strong biological rationale and clinical data, with an interim analysis planned for the second half of 2026. Compugen aims to address unmet medical needs in ovarian cancer treatment, potentially broadening COM701s application. The trial is powered by AI/ML technology, highlighting Compugens pioneering role in predictive computational target discovery.
Product Stage
growth-positive
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target...
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced the dosing of the first patient in a global adaptive platform trial, MAIA-ovarian, to evaluate COM701 as a maintenance therapy for relapsed platinum-sensitive ovarian cancer. The trial is supported by strong biological rationale and clinical data, with an interim analysis planned for the second half of 2026. Compugens AI/ML-powered computational discovery platform underpins its therapeutic development, including COM701, a potential first-in-class anti-PVRIG antibody. The trial aims to assess COM701s efficacy in delaying disease progression and its safety profile. Compugens pipeline includes other promising candidates, and the company is collaborating with AstraZeneca and Gilead on various projects.
Product StagePartners
growth-positive
XOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last?
XOMA Royaltys shares increased by 9% in the last trading session, closing at $26.22, driven by a positive investor outlook on its growing portfolio of assets. The company recently reported strong financial results for Q1 2025, despite an expected quarterly loss of $0.12 per share and a 15% decrease in revenue from the previous year. The consensus EPS estimate for the quarter has been revised 33.9% higher in the last 30 days, indicating potential stock price appreciation. XOMA Royalty is part of the Zacks Medical - Biomedical and Genetics industry and holds a Zacks Rank #3 (Hold).
growth-positive
Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced its participation in upcoming international scientific conferences where it will present its AI/ML-driven predictive computational research. The company is known for its computational target discovery capabilities in cancer biology. Compugen has two proprietary product candidates in Phase 1 development and has partnered with AstraZeneca and Gilead for the development of certain antibodies. The companys pipeline includes early-stage immuno-oncology programs aimed at enhancing anti-cancer immunity. Compugen is headquartered in Israel and its shares are listed on Nasdaq and the Tel Aviv Stock Exchange.
Product StagePartners
growth-positive
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen Ltd., a clinical-stage cancer immunotherapy company, is showcasing its AI/ML-driven predictive computational research at international scientific conferences. The company is a pioneer in computational target discovery and is utilizing its platform to identify new drug targets and biological pathways for cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development and a PD-1/TIGIT bispecific antibody in Phase 3 development through a partnership with AstraZeneca. Additionally, a high-affinity anti-IL-18 binding protein antibody is licensed to Gilead. The companys efforts highlight its scientific capabilities and strategic partnerships in advancing cancer treatment.
Product StagePartners
growth-negative
These Analysts Just Made An Incredible Downgrade To Their Compugen Ltd. (NASDAQ:CGEN) EPS Forecasts
Analysts have significantly downgraded their forecasts for Compugen Ltd., leading to a negative outlook for the company. Revenue and earnings per share (EPS) estimates have been revised downward, with a projected 49% decline in sales by 2025 and an 82% increase in losses per share. This contrasts sharply with the industry, which is expected to grow by 17% annually. The downgrade suggests that Compugens performance will be substantially worse than its peers, causing concern among investors. Despite a recent 4.3% increase in share price, the negative sentiment from analysts could lead to caution among shareholders.
growth-negative
Compugen First Quarter 2025 Earnings: Misses Expectations
Compugen reported a revenue of US$2.28 million, which is down 11% from the previous quarter and missed analyst estimates by 38%. The net loss was US$7.18 million, slightly narrowed by 1.2% from the previous quarter. Earnings per share also missed estimates by 45%. Despite these setbacks, the companys shares have risen by 5.3% over the past week. Looking forward, revenue is forecasted to grow by 15% annually over the next three years, slightly below the industry average of 17%. The article highlights investment risks and warning signs associated with Compugen, urging investors to consider these factors.
growth-negative
Compugen Ltd (CGEN) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Revenue Decline
Compugen Ltd is advancing its clinical immuno-oncology pipeline, focusing on innovative therapies. The company has initiated a sub-trial for their anti-PVRIG antibody COM701 in ovarian cancer. Despite a strong cash position and partnership with AstraZeneca, the company faces challenges due to decreased revenues and a net loss in Q1 2025. The competitive landscape in ovarian cancer is evolving, with new therapies potentially impacting Compugens strategy. The success of their TIGIT program is contingent on positive outcomes from upcoming Phase 3 trials. The company is exploring novel mechanisms of action to enhance anticancer immunity.
Product StagePartnersCustomers
growth-negative
Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates
Compugen reported a quarterly loss of $0.08 per share, which was worse than the Zacks Consensus Estimate of a $0.06 loss, marking a negative earnings surprise of 33.33%. The company also missed revenue expectations, posting $2.28 million versus the expected $3.71 million. Over the past year, Compugen has only surpassed consensus EPS estimates once. The companys stock has underperformed the market, losing 9.2% since the beginning of the year compared to the S&P 500s gain of 1.3%. The future performance of the stock will depend on managements commentary and changes in earnings estimates, with the current Zacks Rank being #3 (Hold).
growth-positive
Compugen Reports First Quarter 2025 Results
Compugen Ltd., a clinical-stage cancer immunotherapy company, reported its financial results for Q1 2025 and provided a corporate update. The company is advancing its diverse pipeline, including the initiation of a trial for COM701 maintenance therapy and a Phase 1 trial for GS-0321, licensed to Gilead. Partner AstraZeneca expanded its rilvegostomig program to ten Phase 3 trials, potentially generating significant revenue for Compugen. The company maintains a solid financial position with a cash runway into 2027, enabling continued use of its AI/ML-powered discovery platform, Unigen™. Leadership changes are planned for September 2025, with Dr. Eran Ophir becoming President and CEO.
Product StagePartnersManagement Changes
growth-negative
Compugen: Q1 Earnings Snapshot
Compugen Ltd., a drug developer based in Holon, Israel, reported a loss of $7.2 million for the first quarter, equating to a loss of 8 cents per share. The company generated $2.3 million in revenue during this period. Compugens shares closed at $1.37, down from $2.11 a year ago. This financial performance indicates a negative impact on the companys growth. The article was generated using data from Zacks Investment Research.
growth-positive
Initiated platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in Q2 2025 Recruitment ongoing in the first in human...
Compugen Ltd., a clinical-stage cancer immunotherapy company, reported its financial results for Q1 2025 and provided a corporate update. The company is advancing its clinical and early-stage pipeline, including the initiation of a trial for COM701 maintenance therapy for ovarian cancer and a Phase 1 trial for GS-0321, licensed to Gilead. Partner AstraZeneca is expanding its rilvegostomig program to ten Phase 3 trials. Compugen maintains a strong financial position with a cash runway into 2027 and plans leadership changes in September 2025. The company continues to leverage its AI/ML-powered platform, Unigen™, for research.
Product StagePartnersManagement Changes
growth-positive
Compugen Announces Leadership Transitions Effective September 2025
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced significant leadership changes to take effect in September 2025. Anat Cohen-Dayag, Ph.D., will transition from her role as President and CEO to Executive Chair of the Board of Directors, while Eran Ophir, Ph.D., will become the new President and CEO. These changes are subject to shareholder approval. The company, known for its AI/ML-driven computational discovery platform, has strategic partnerships with AstraZeneca and Gilead. The leadership transition aims to strengthen Compugens corporate strategy and investor relations. The outgoing Chair, Paul Sekhri, expressed confidence in the new leadership team. The company is poised for growth with a cash runway into 2027.
Management ChangesPartners
growth-positive
Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced it will release its first quarter 2025 financial results on May 19, 2025. The company utilizes a predictive computational discovery platform to identify new drug targets for cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development and a bispecific antibody in Phase 3 development through a license agreement with AstraZeneca. Additionally, a high-affinity anti-IL-18 binding protein antibody is in Phase 1 development, licensed to Gilead. The company is headquartered in Israel, with offices in San Francisco, and its shares are listed on Nasdaq and the Tel Aviv Stock Exchange.
Product StagePartners
growth-positive
Compugen to Participate in Multiple Virtual Investor Conferences in April 2025
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced its participation in several virtual investor conferences in April 2025. The company is known for its computational target discovery platform, UnigenTM, and has two proprietary product candidates in Phase 1 development: COM701 and COM902. Additionally, AstraZeneca is developing Rilvegostomig, a PD-1/TIGIT bispecific antibody, in Phase 3 through a license agreement with Compugen. Another product, GS-0321, is licensed to Gilead and is in Phase 1 development. Compugens participation in these conferences highlights its ongoing efforts in cancer immunotherapy and its strategic partnerships with companies like AstraZeneca and Gilead.
Product StagePartners
growth-positive
Compugen Ltd. (CGEN): Among the Penny Stocks With Huge Upside Potential According to Analysts
The article discusses the potential of penny stocks, specifically focusing on Compugen Ltd. (NASDAQ:CGEN) and its position among other penny stocks with significant upside potential. Penny stocks, typically trading below $5, are attractive to investors seeking high returns with minimal initial investment. Despite recent struggles of small-cap and mid-cap companies to keep pace with large-cap stocks, analysts predict a favorable market for these smaller firms in 2025. Factors such as the Federal Reserve cutting rates, a pro-business administration, and potential mergers and acquisitions are expected to benefit small and mid-cap stocks. The article also highlights the potential impact of deregulation and macroeconomic conditions on these stocks.
growth-negative
Calculating The Intrinsic Value Of Compugen Ltd. (NASDAQ:CGEN)
The article discusses the intrinsic value estimation of Compugen Ltd. using the Discounted Cash Flow (DCF) model. The analysis suggests that Compugens current share price of US$1.81 is close to its fair value of US$1.92, which is significantly lower than the analyst price target of US$4.00. The DCF model used is a 2-stage model, which considers two different growth phases for the companys cash flows. The article highlights the importance of discounting future cash flows to their present value and provides a detailed breakdown of expected cash flows from 2025 to 2034. The analysis indicates a conservative growth rate for future cash flows beyond the initial 10-year period.
growth-positive
Compugen Ltd (CGEN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Compugen Ltd reported a net loss of $14.2 million for 2024, with revenues decreasing to $27.9 million from $33.5 million in 2023. Despite this, the company maintains a strong cash position, expected to last into 2027, and is advancing its cancer treatment pipeline. Compugen received a $30 million milestone payment from Gilead for FDA IND clearance of GS-0321, highlighting its development capabilities. AstraZenecas initiation of seven Phase 3 trials with rilvegostomig, derived from Compugens COM902, presents a significant revenue opportunity. The company is focusing on advancing COM701 for ovarian cancer treatment, although the exploratory nature of the study may limit its impact. Overall, the article suggests a positive outlook for Compugens strategic priorities and clinical advancements.
Product StageInvestmentCustomers
growth-negative
Compugen (CGEN) Reports Q4 Loss, Misses Revenue Estimates
Compugen reported a quarterly loss of $0.07 per share, missing the Zacks Consensus Estimate of $0.07, and representing an earnings surprise of -200%. The company, which operates in the biomedical and genetics industry, posted revenues of $1.47 million for the quarter ended December 2024, significantly below the consensus estimate. Despite outperforming the market with an 18.3% share price increase since the beginning of the year, the companys earnings outlook remains uncertain. The Zacks Rank for Compugen is currently #3 (Hold), indicating expectations for the stock to perform in line with the market. The companys future performance will depend on managements commentary and changes in earnings estimates.
growth-positive
/C O R R E C T I O N -- Compugen Ltd./
Compugen Ltd., a clinical-stage cancer immunotherapy company, reported its financial results for the fourth quarter and full year 2024. The company is advancing its COM701, an anti-PVRIG antibody, for use as a maintenance therapy in platinum-sensitive ovarian cancer, with trials set to begin in Q2 2025. Additionally, Compugens partner AstraZeneca has expanded its rilvegostomig program, derived from Compugens COM902, to seven Phase 3 trials. This partnership could lead to significant revenue through milestone payments and royalties. Compugens strong financial position is expected to support operations through 2027, and the company is focused on executing its innovative pipeline in 2025.
Product StagePartners
growth-negative
Compugen: Q4 Earnings Snapshot
Compugen Ltd., a drug developer based in Holon, Israel, reported a fourth-quarter loss of $6.1 million, translating to a loss of 7 cents per share. This result fell short of Wall Street expectations, which anticipated earnings of 7 cents per share. The companys revenue for the period was $1.5 million, also missing the forecasted $17.5 million. For the year, Compugens loss narrowed to $14.2 million, or 16 cents per share, with total revenue reported at $27.9 million. The companys shares closed at $1.81, down from $2.64 a year ago.
growth-positive
Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced its participation in a fireside chat at the Leerink Partners Global Healthcare Conference on March 11, 2025. The company is utilizing its predictive computational discovery platform, Unigen™, to develop cancer immunotherapies. Compugen has two proprietary product candidates, COM701 and COM902, in Phase 1 development, and a bispecific antibody, Rilvegostomig, in Phase 3 development through a partnership with AstraZeneca. Additionally, GS-0321 is in Phase 1 development under a license agreement with Gilead. The companys pipeline focuses on enhancing anti-cancer immunity.
Product StagePartners
growth-positive
Gene structure information identified by combining Compugen's AI/ML predictive computational discovery platform, Unigen™ with Ultima's UG 100™ sequencing...
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced results from a collaboration with Ultima Genomics. The partnership combines Compugens AI/ML-powered discovery platform, Unigen, with Ultimas UG 100 sequencing platform to gain insights into gene structure for immuno-oncology. The collaboration aims to enhance Compugens gene sequencing database and develop new cancer immunotherapies. The research was presented at the Advances in Genome Biology and Technology (AGBT) 2025 General Meeting. Compugen plans to further utilize Ultimas technology to accelerate the discovery of new immunotherapies. The collaboration highlights the potential of AI/ML and large-scale data in transforming cancer research.
Partners
growth-positive
Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology
Compugen Ltd., a clinical-stage cancer immunotherapy company, has announced the results of a joint research collaboration with Ultima Genomics. The collaboration combines Compugens AI/ML-powered predictive computational discovery platform, Unigen, with Ultimas UG 100 sequencing platform to gain new insights into gene structure for immuno-oncology. The research, presented at the Advances in Genome Biology and Technology (AGBT) 2025 General Meeting, highlights the potential of combining AI/ML techniques with advanced sequencing technology to uncover new drug targets and develop cancer immunotherapies. This collaboration is seen as a growth-positive development for Compugen, enhancing its capabilities in predictive computational discovery.
Partners
growth-positive
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced it will release its Q4 and full-year 2024 financial results on March 4, 2025. The company specializes in computational target discovery and has proprietary product candidates in Phase 1 development, including COM701 and COM902. Additionally, Compugen has a partnership with AstraZeneca for the development of a bispecific antibody, rilvegostomig, which is in Phase 3 development. Another product, GS-0321, is licensed to Gilead. Compugen is headquartered in Israel and listed on Nasdaq and the Tel Aviv Stock Exchange. The announcement is expected to positively impact the companys growth.
Product StagePartners
growth-positive
Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced it will release its fourth quarter and full year 2024 financial results on March 4, 2025. The company is known for its computational target discovery platform and has several product candidates in various stages of development. Notably, COM701 and COM902 are in Phase 1 development, while a bispecific antibody, Rilvegostomig, is in Phase 3 development through a partnership with AstraZeneca. Additionally, GS-0321 is in Phase 1 development and licensed to Gilead. Compugen is headquartered in Israel and listed on Nasdaq and the Tel Aviv Stock Exchange.
Product StagePartners
growth-positive
Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025. The company utilizes its predictive computational discovery platform, UnigenTM, to identify new drug targets and biological pathways for cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development and a PD-1/TIGIT bispecific antibody in Phase 3 development through a partnership with AstraZeneca. Additionally, COM503 is licensed to Gilead. The companys pipeline focuses on addressing immune resistance mechanisms, and it is listed on Nasdaq and the Tel Aviv Stock Exchange.
Product StagePartners
growth-positive
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025. The company is known for its computational discovery platform, UnigenTM, which aids in identifying new drug targets and pathways for cancer immunotherapies. Compugen has several product candidates in various stages of development, including COM701 and COM902 in Phase 1, and a PD-1/TIGIT bispecific antibody in Phase 3 development by AstraZeneca. Additionally, COM503 is licensed to Gilead. The company is headquartered in Israel with offices in San Francisco, and its shares are traded on Nasdaq and the Tel Aviv Stock Exchange.
Product StagePartners
growth-positive
Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors
Compugen Ltd., a clinical-stage cancer immunotherapy company, has announced the dosing of the first patient in a Phase 1 clinical trial for COM503, an anti-IL-18 binding protein antibody. Licensed to Gilead Sciences, Inc., COM503 aims to harness cytokine biology to treat cancer. The trial, initiated in Q4 2024, will evaluate the safety and tolerability of COM503 as monotherapy and in combination with Gileads anti-PD1, zimberelimab, in patients with advanced solid tumors. Compugen is responsible for running the trial, which presents a unique opportunity to enhance anti-tumor immune responses by releasing IL-18 within tumors.
Product StagePartners
growth-negative
The past five years for Compugen (NASDAQ:CGEN) investors has not been profitable
Compugen Ltd. has experienced a significant decline in its share price over the past five years, dropping by 74%. Despite becoming profitable and achieving a 75% increase in revenue during this period, the companys share price has continued to fall, including an 11% decrease in the last three months. Investors have faced a tough year with a 10% loss, contrasting with a market gain of about 26%. The article suggests that while Compugen has improved its bottom line, there is a need for sustained improvements in key metrics to generate investor enthusiasm. The article also highlights the importance of understanding investment risks associated with the company.
growth-positive
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen Ltd., a clinical-stage cancer immunotherapy company, has been granted a new U.S. patent for its COM902 antibody. This patent covers the use of COM902 in combination with anti-PD-1 and anti-PVRIG antibodies for cancer treatment, strengthening Compugens intellectual property portfolio. The patent is expected to expire no earlier than August 2037. Compugens strategy focuses on innovative treatments and shareholder value, with ongoing studies to evaluate the efficacy of its antibodies. The company collaborates with AstraZeneca and Gilead on various projects. Compugen is headquartered in Israel and listed on Nasdaq and the Tel Aviv Stock Exchange.
growth-positive
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies
Compugen Ltd., a clinical-stage cancer immunotherapy company, has announced the granting of a new patent by the United States Patent and Trademark Office. This patent covers the method of use for COM902, a clinical-stage antibody targeting TIGIT, in combination with any anti-PD-1 and anti-PVRIG antibodies for cancer treatment. This development strengthens Compugens intellectual property portfolio, particularly in the DNAM-1 axis checkpoint inhibitors. The patent is expected to expire no earlier than August 2037. Compugen is leveraging its computational discovery platform to identify new drug targets and pathways for cancer immunotherapies. The company has ongoing partnerships with AstraZeneca and Gilead for the development of its therapeutic pipeline.
growth-negative
Compugen Ltd. (NASDAQ:CGEN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Compugen has experienced a 19% decline in its share price over the past three months. Despite this, the companys financial indicators suggest potential for long-term growth, as its return on equity (ROE) stands at 2.6%. This indicates that for every dollar of shareholder investment, Compugen generates a profit of $0.03. Although this ROE is below the industry average of 18%, Compugen has seen a moderate 10% net income growth over the past five years. However, this growth is still lower than the industry average of 19%. The article suggests that strategic management decisions or a low payout ratio might be positively influencing Compugens earnings growth.
growth-positive
Compugen Ltd (CGEN) Q3 2024 Earnings Call Highlights: Promising Developments and Strategic ...
Compugen Ltd reported promising data from their studies on COM701, COM902, and pembrolizumab in patients with platinum-resistant ovarian cancer, showing durable responses and good tolerability. The company received a $30 million milestone payment from Gilead for achieving FDA IND clearance for COM503, highlighting progress in their partnership. Compugen has a strong cash position of $113.2 million, expected to fund operations into 2027. They plan to initiate a new trial in Q2 2025, targeting relapsed platinum-sensitive ovarian cancer patients, which could open new regulatory and commercial opportunities. The company is eligible for future milestone payments and royalties from AstraZenecas development of bispecific antibodies. Despite a low response rate in the study, Compugen aims to address toxicity and side effects of current treatments. Their future success relies on ongoing and planned clinical trials.
CustomersPartners
growth-positive
Clinical data presented at SITC 2024 demonstrated COM701 (anti-PVRIG) mediated anti-tumor activity with durable responses and good tolerability profile in...
Compugen Ltd., a clinical-stage cancer immunotherapy company, presented promising clinical data at SITC 2024, showcasing the efficacy of its COM701 and COM503 treatments. The company plans to initiate new trials in 2025 and 2024, respectively, targeting ovarian and solid tumors. Compugens partner, AstraZeneca, is advancing rilvegostomig into additional Phase 3 trials, potentially increasing revenue through milestone payments and royalties. Financially, Compugen reported a net profit for Q3 2024, driven by milestone payments from Gilead and AstraZeneca, and expects its cash reserves to support operations until 2027. The company is focused on expanding its therapeutic pipeline and leveraging partnerships to enhance its market position.
PartnersInvestment
growth-positive
Compugen Reports Third Quarter 2024 Results
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced promising clinical data for its drug COM701 at SITC 2024. The data showed anti-tumor activity and good tolerability in patients with tumors typically unresponsive to immunotherapy. Compugen plans to start an adaptive platform trial in Q2 2025 for relapsed platinum-sensitive ovarian cancer patients. The company is also on track to initiate a Phase 1 trial for COM503 in Q4 2024. Partner AstraZeneca reported positive data for rilvegostomig and advanced it into two Phase 3 trials. Compugens strong financial position is expected to support its clinical advancements into 2027. The company sees regulatory and commercial opportunities in targeting ovarian cancer patients with limited treatment options.
PartnersExpand
growth-positive
Compugen: Q3 Earnings Snapshot
Compugen Ltd., a drug development company based in Holon, Israel, reported a net income of $1.3 million for its third quarter, translating to 1 cent per share. The company generated $17.1 million in revenue during this period. Compugens shares closed at $1.74, a significant increase from 60 cents a year ago, indicating positive financial growth. This report was generated using data from Zacks Investment Research.
growth-negative
Compugen (CGEN) Q3 Earnings and Revenues Lag Estimates
Compugen reported quarterly earnings of $0.01 per share, which missed the Zacks Consensus Estimate of $0.06 per share, marking an earnings surprise of -83.33%. The company posted revenues of $17.13 million for the quarter ended September 2024, missing the consensus estimate by 3.05%. Despite surpassing consensus EPS estimates three times in the last four quarters, Compugen shares have lost about 12.1% since the beginning of the year, underperforming the S&P 500s gain of 25.8%. The companys earnings outlook and estimate revisions are mixed, resulting in a Zacks Rank #3 (Hold). The future performance of Compugens stock will depend on managements commentary and changes in earnings expectations.
growth-positive
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced its participation in a fireside chat at the Stifel 2024 Healthcare Conference in New York City on November 18, 2024. The company is known for its predictive computational discovery platform, UnigenTM, which aids in identifying new drug targets and biological pathways for cancer immunotherapies. Compugen has several product candidates in various stages of development, including COM701 and COM902, targeting solid tumors. Additionally, the company has a licensing agreement with AstraZeneca for the development of bispecific and multispecific antibodies and with Gilead for COM503, an anti-IL-18 binding protein antibody. Compugen is headquartered in Israel and has offices in San Francisco, with shares listed on Nasdaq and the Tel Aviv Stock Exchange.
growth-positive
Compugen to Participate in Stifel 2024 Healthcare Conference
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced its participation in a fireside chat at the Stifel 2024 Healthcare Conference in New York City on November 18, 2024. The company is known for its computational discovery platform, UnigenTM, which aids in identifying new drug targets and biological pathways for cancer immunotherapies. Compugen has several product candidates in various stages of development, including COM701 and COM902, targeting solid tumors. A bispecific antibody, rilvegostomig, is in Phase 3 development through a license agreement with AstraZeneca. Additionally, an early-stage program, COM503, has been licensed to Gilead. Compugen is headquartered in Israel, with offices in San Francisco, and its shares are listed on Nasdaq and the Tel Aviv Stock Exchange.
growth-positive
Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced promising data on the anti-tumor activity and safety profile of its triple combination therapy COM701, COM902, and pembrolizumab in patients with platinum-resistant ovarian cancer. The data, presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, showed durable objective responses in late-stage ovarian cancer patients. The study highlights the potential of COM701 as a differentiated immune checkpoint inhibitor with a favorable safety profile. Compugen is encouraged by the data and feedback from experts, supporting the advancement of COM701 to earlier stages of ovarian cancer therapy. The company aims to address the unmet need for effective treatments in relapsed ovarian cancer.
growth-positive
Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced it will release its third quarter 2024 financial results on November 12, 2024. The company will host a conference call and webcast to review the results and provide a corporate update. Compugen is known for its computational discovery platform, Unigen™, and has several product candidates in development, including COM701 and COM902. The company has a partnership with AstraZeneca for the development of bispecific and multispecific antibodies, and its COM503 program is licensed to Gilead. Compugen is headquartered in Israel and listed on Nasdaq and the Tel Aviv Stock Exchange.
growth-positive
Compugen Gears Up to Report Q3 Earnings: Here's What to Expect
Compugen Ltd. is focusing on the development of its oncology pipeline candidates as it prepares to report its third-quarter 2024 earnings. The companys revenue is primarily from its licensing agreements with Gilead Sciences and AstraZeneca. A recent FDA clearance for Compugens investigational drug, COM503, triggered a $30 million milestone payment from Gilead, expected to be recorded in the third quarter. Compugen is also working on a triple combination study involving its products and Mercks Keytruda for ovarian cancer. AstraZeneca, a partner, is developing a bi-specific derived from Compugens COM902, which could lead to future royalties for Compugen. Despite a decline in shares, Compugen has shown a mixed earnings surprise history, with a significant earnings beat in the last quarter.
CustomersPartners
growth-positive
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced new clinical data supporting the anti-tumor activity and safety of a triple combination therapy in patients with platinum-resistant ovarian cancer. The data will be presented at the 39th Annual Meeting of the Society for Immunotherapy of Cancer in November 2024. Compugens proprietary product candidates, COM701 and COM902, are in Phase 1 development, with COM902 being part of a Phase 3 trial by AstraZeneca through a licensing agreement. The company is also working on early-stage immuno-oncology programs, including COM503, licensed to Gilead. Compugen is headquartered in Israel and listed on Nasdaq and the Tel Aviv Stock Exchange.
Partners
growth-positive
Compugen to Present New Clinical Data at SITC 2024
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced new clinical data supporting the anti-tumor activity and safety of its triple combination therapy COM701, COM902, and pembrolizumab in patients with platinum-resistant ovarian cancer. The data will be presented at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in November 2024. Compugens pipeline includes several proprietary product candidates in various stages of development, including a Phase 3 program licensed to AstraZeneca and an early-stage program licensed to Gilead. The announcement highlights Compugens ongoing efforts in developing innovative cancer immunotherapies and its strategic partnerships with major pharmaceutical companies.
Partners
growth-positive
Compugen (CGEN) Upgraded to Strong Buy: What Does It Mean for the Stock?
Compugen (CGEN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting an upward trend in earnings estimates. This upgrade is based on the Zacks rating system, which tracks EPS estimates from sell-side analysts. The upgrade indicates a positive earnings outlook for Compugen, which could lead to increased buying pressure and a higher stock price. The Zacks Rank system has a strong track record, with Rank #1 stocks generating an average annual return of +25% since 1988. Compugen is expected to earn $0.07 per share for the fiscal year ending December 2024, a 133.3% year-over-year change. Over the past three months, the Zacks Consensus Estimate for Compugen has increased by 31.3%.
growth-positive
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced that Dr. Roy Granit will present a poster on applying AI to gain insights into the novel immune checkpoint PVRIG at the Single Cell Genomics 2024 conference in Greece. The poster will highlight the use of Compugens AI/ML-powered computational discovery platform, Unigen™, which has been instrumental in identifying novel drug targets and developing cancer immunotherapies. The platform integrates various biological data and has yielded multiple novel immuno-oncology drug targets. Compugens therapeutic pipeline includes proprietary product candidates in Phase 1 development and partnerships with pharmaceutical companies like AstraZeneca and Gilead.
Partners
growth-positive
Compugen to Present at Single Cell Genomics 2024 Conference
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced that Dr. Roy Granit will present a poster on applying AI to gain insights into the novel immune checkpoint PVRIG at the Single Cell Genomics 2024 conference in Greece. The presentation will highlight the use of Compugens AI/ML-powered computational discovery platform, Unigen™, which has been instrumental in identifying novel drug targets and developing cancer immunotherapies. The platform integrates various biological data to predict new drug targets and understand complex biology. Compugens pipeline includes proprietary product candidates in clinical development and partnerships with pharmaceutical companies like AstraZeneca and Gilead.
Partners
growth-positive
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced that its management will present virtually at the H.C. Wainwright 26th Annual Global Investment Conference. The presentation will be available on demand on Compugens website from September 9, 2024, for 30 days. Compugen is known for its predictive computational discovery capabilities and has multiple proprietary product candidates in various stages of development. Notably, its anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement. Additionally, its anti-IL-18 binding protein antibody, COM503, has been granted IND clearance from the FDA and is licensed to Gilead.
Partners
growth-positive
Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced that its management will present virtually at the H.C. Wainwright 26th Annual Global Investment Conference. The presentation will be available on demand on the Investor Relations section of Compugens website from September 9, 2024. Compugen specializes in predictive computational discovery for cancer immunotherapies and has several proprietary product candidates in various stages of development. Notably, their COM701 and COM902 antibodies are in Phase 1 development, while a bispecific antibody derived from COM902 is in Phase 3 development through a license agreement with AstraZeneca. Additionally, their COM503 program, licensed to Gilead, has received IND clearance from the FDA.
Partners
growth-positive
Can Compugen (CGEN) Run Higher on Rising Earnings Estimates?
Compugen (CGEN) has shown solid improvement in earnings estimates, driving short-term price momentum. Analysts optimism on the drug developers earnings prospects has led to higher estimates, reflected in its stock price. The Zacks Rank system, which rates stocks from #1 (Strong Buy) to #5 (Strong Sell), has given Compugen a #1 rank due to the positive revisions. The company is expected to earn $0.06 per share for the current quarter, a 154.55% year-over-year increase, and $0.07 per share for the full year, a 133.33% increase. Over the past month, the consensus estimate has risen by 31.25%. Compugen shares have gained 15.3% in the past four weeks.
growth-positive
Party Time: Brokers Just Made Major Increases To Their Compugen Ltd. (NASDAQ:CGEN) Earnings Forecasts
Analysts have upgraded their near-term forecasts for Compugen Ltd., predicting revenues of $45m in 2024, a 5.0% increase on its sales over the past 12 months. They also expect the company to turn profitable soon, forecasting $0.04 in per-share earnings. Previously, they had been forecasting revenues of $41m and losses of $0.05 per share in 2024. However, Compugens revenue growth is expected to slow, with the forecast 10% annualised growth rate until the end of 2024 being well below the historical 66% p.a. growth over the last five years.
None
growth-positive
Compugen Ltd. (NASDAQ:CGEN): When Will It Breakeven?
Compugen Ltd., a clinical-stage therapeutic discovery and development company, is approaching a major milestone in its business. The companys loss has lessened from a US$19m loss in the full financial year to a trailing-twelve-month loss of US$17m. Analysts predict that the company will reach breakeven just over a year from today, with positive profits of US$25m expected in 2025. The company is expected to grow 50% year-on-year, on average, to reach this point. Compugen currently has no debt on its balance sheet, which is rare for a loss-making biotech company.
Investment
Growth-Negative
Compugen (CGEN) Reports Q2 Loss, Tops Revenue Estimates
Compugen reported a quarterly loss of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.08. This represents an earnings surprise of 75%. The company, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $6.7 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 150.54%. However, Compugen shares have lost about 17.2% since the beginning of the year. The companys earnings outlook and the performance of the industry will have a significant impact on the stocks future performance.
growth-positive
Compugen Reports Second Quarter 2024 Results
Compugen Ltd., a clinical-stage cancer immunotherapy company, has announced its financial results for Q2 2024. The company received FDA IND clearance for COM503, triggering a $30 million milestone payment from Gilead. Compugen is also set to present data from its COM701 + COM902 + pembrolizumab study in platinum-resistant ovarian cancer in Q4 2024. Partner AstraZeneca is advancing the development of rilvegostomig, with a non-risk adjusted peak year revenue target of over $5 billion. Compugen reported approximately $6.7 million in revenues for Q2 2024, and expects its cash runway to fund operations into 2027.
PartnersInvestment
growth-negative
Compugen: Q2 Earnings Snapshot
Compugen Ltd., a drug developer based in Holon, Israel, reported a loss of $2.1 million for its second quarter. The company posted a revenue of $6.7 million for the same period. Despite the loss, the companys shares closed at $1.64, up from $1.12 a year ago.
Investment
growth-positive
Compugen receives FDA approval for Phase I trial of solid tumour treatment
The US Food and Drug Administration (FDA) has approved an investigational new drug (IND) application from Compugen to begin a Phase I trial of COM503, a drug candidate designed to treat solid tumours. The FDA’s IND clearance triggered a $30m milestone payment to Compugen from Gilead. Last year, Compugen signed a licensing agreement giving Gilead exclusive rights for developing and commercialising anti-IL-18 binding protein antibodies, including COM503. Under this agreement, Compugen is responsible for the preclinical development and the anticipated Phase I trial, while Gilead will have exclusive rights to further develop and commercialise COM503 after the trial.
InvestmentPartners
growth-positive
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors
Compugen Ltd., a clinical-stage cancer immunotherapy company, has announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application to initiate a Phase 1 trial for COM503, a potential first-in-class, high affinity anti-IL-18 binding protein antibody licensed to Gilead Sciences, Inc. The IND clearance triggered a $30 million milestone payment from Gilead. The Phase 1 trial in solid tumors is expected to begin in the fourth quarter of 2024.
InvestmentPartners
Neutral
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced that it will release its second quarter 2024 financial results on August 6, 2024. The company will host a conference call and webcast to review the results and provide a corporate update. Compugen has developed two proprietary product candidates for the treatment of solid tumors and has a therapeutic pipeline of early-stage immuno-oncology programs. The companys shares are listed on Nasdaq and the Tel Aviv Stock Exchange.
Public Trading
Growth-Negative
Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data
Lexeo Therapeutics shares fell by 26% following the release of positive interim data from two cohorts of the phase I/II SUNRISE-FA study evaluating LX2006, a gene therapy for treating Friedreich ataxia (FA) cardiomyopathy. Despite the positive results, investors raised concerns that the data was not sufficient to warrant accelerated FDA approval. Furthermore, the data did not show that patients function improved after treatment with LX2006. This is likely the reason for the share price decline. Lexeo plans to report additional data later this year and is currently dosing patients in the third dose cohort of the SUNRISE-FA study.
CustomersManagement Changes
growth-positive
Verona (VRNA) Stock Surges 36% in the Past Month: Here's Why
Verona Pharmas shares have increased by 36.3% over the past month following the FDAs approval of its lead pipeline drug, Ohtuvayre, for the treatment of chronic obstructive pulmonary disease (COPD). This approval makes Ohtuvayre the first inhaled product with a novel mechanism of action available as COPD maintenance treatment in over 20 years. The drug is expected to be commercially launched in Q3 2024. The approval has also put Verona ahead of Sanofi and Regenerons drug Dupixent, which is currently under FDA review for label expansion in COPD indication.
CustomersInvestment
growth-negative
Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View
Indivior plcs shares dropped by 34% after the company lowered its financial outlook for 2024 and announced plans to discontinue sales of its schizophrenia drug, Perseris. The company cited adverse sales conditions for its top-selling medication, Sublocade, as the reason for the revision. The company also plans to reduce its headcount by nearly 130 employees. Despite the reduced guidance for Sublocade, management remains confident in the drugs long-term sales performance. Indivior also announced a settlement with multiple plaintiffs, including Health Care Service Corp. and Molina Healthcare, to resolve an antitrust lawsuit, agreeing to pay $85 million in cash.
CustomersLayoffs
Growth-Negative
The past three years for Compugen (NASDAQ:CGEN) investors has not been profitable
Compugen Ltd.s share price has dropped 78% in the last three years and 25% in the last quarter, which is concerning for long-term shareholders. Despite the companys revenue growing at 81% per year over three years, the share price has fallen 21% per year in the same period. This discrepancy suggests there may be an issue with profitability. Although Compugen has rewarded shareholders with a total return of 52% in the last year, the long-term loss makes the future uncertain.
Public Trading
growth-positive
Compugen to Present at Upcoming Antibody Industrial Symposium
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced that Pierre Ferré, SVP of Preclinical Development and Corporate Operations, will present a case study on clinical dose selection for TIGIT monospecific and bispecific antibodies at the Antibody Industrial Symposium in Montpellier, France on June 21, 2024. Compugen has developed two proprietary product candidates, COM701 and COM902, for the treatment of solid tumors. The companys therapeutic pipeline of early-stage immuno-oncology programs aims to address various mechanisms of immune resistance.
PartnersCustomers
Growth-Positive
Compugen (CGEN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Compugen (CGEN) has been experiencing a downtrend, with the stock losing 10.3% over the past week. However, a hammer chart pattern formed in its last trading session, indicating a potential trend reversal. This pattern suggests that the bulls have been able to counteract the bears to help the stock find support. Additionally, rising optimism among Wall Street analysts about the future earnings of this drug developer is a solid fundamental factor that enhances the prospects of a trend reversal for the stock. Over the last 30 days, the consensus EPS estimate for the current year has increased 220%, and CGEN currently has a Zacks Rank #2 (Buy).
growth-positive
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
Compugen Ltd., a clinical-stage cancer immunotherapy company, has announced it is entitled to receive a $5 million milestone payment from AstraZeneca. This follows the dosing of the first patient in a Phase 3 trial evaluating rilvegostomig, AstraZenecas PD-1/TIGIT bispecific antibody, which is derived from Compugens clinical-stage anti-TIGIT antibody, COM902. The trial is being sponsored by AstraZeneca in collaboration with Daiichi Sankyo and is expected to enrol approximately 675 patients in more than 14 countries.
PartnersInvestment
growth-positive
Earnings Release: Here's Why Analysts Cut Their Compugen Ltd. (NASDAQ:CGEN) Price Target To US$5.00
Compugen Ltd. has released its first-quarter report, with revenue exceeding expectations at $2.6m, a 111% beat. Although the company reported a statutory loss of $0.08 per share, this was smaller than analysts predicted. Analysts are forecasting revenues of $37.0m in 2024, reflecting a 2.8% increase on its revenue over the past 12 months. The loss per share is expected to reduce by 73% to $0.05. Despite the dip in revenue estimates, analysts have improved sentiment, with a promising decrease in losses per share.
Customers
growth-positive
Compugen Reports First Quarter 2024 Results
Compugen Ltd., a clinical-stage cancer immunotherapy company, has announced its financial results for Q1 2024, revealing a solid balance sheet and extended cash runway expected to fund operations into 2027. The company also provided updates on its ongoing clinical trials, including the completion of enrollment for its COM701 + COM902 + pembrolizumab platinum resistant ovarian cancer study, with data expected to be presented in Q4 2024. Compugens partner, AstraZeneca, has progressed rilvegostomig into its second Phase 3 trial in nonsquamous NSCLC, making Compugen eligible for development milestone payments for this second indication.
CustomersPartnersInvestment
Growth-Negative
Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates
Biomedical company Compugen reported a quarterly loss of $0.08 per share, beating the Zacks Consensus Estimate of a $0.10 loss per share. This is an improvement from the $0.11 loss per share reported a year ago. Despite this, the companys revenues of $2.56 million for the quarter ending March 2024 missed the Zacks Consensus Estimate by 8.28%. The companys shares have increased by 6.6% since the beginning of the year, underperforming the S&P 500s gain of 11.2%. The companys future performance is expected to align with the market, given its current Zacks Rank of #3 (Hold).
Management Changes
growth-positive
Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential
Compugen Ltd., a clinical-stage cancer immunotherapy company, has announced the publication of a peer-reviewed paper on the role of PVRIG in cancer. The paper provides an advanced understanding of the unique biology of PVRIG and its role in cancer. The companys research has led to the discovery of the novel immune checkpoint PVRIG and the potential synergy in blocking PVRIG, TIGIT and PD-1 pathways. The company has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumours.
InvestmentPartners
growth-positive
Compugen Appoints David Silberman as Chief Financial Officer
Compugen Ltd., a clinical-stage cancer immunotherapy company, has announced the appointment of David Silberman as its new Chief Financial Officer effective August 15, 2024. Silberman will take over from Alberto Sessa, who will depart Compugen on the same day. Silberman joins Compugen from Oramed Pharmaceuticals Inc., where he served as Chief Financial Officer. He has over 15 years of experience in finance, including 10 years in the healthcare and biotech industries.
Management Changes
Growth-Positive
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced that it will release its first quarter 2024 financial results on May 20, 2024. The company will host a conference call and webcast to review the results and provide a corporate update. Compugen is known for its predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. The company has developed two proprietary product candidates and has a clinical stage partnered program with AstraZeneca. It also has a therapeutic pipeline of early-stage immuno-oncology programs.
Public Trading
growth-positive
We're Not Worried About Compugen's (NASDAQ:CGEN) Cash Burn
Compugens share price has soared by 240% over the last year, despite the company being unprofitable. The companys cash burn is increasing, up 4.2% in the last year, but its operating revenue has also increased by 346% in the same period. As of December 2023, Compugen had cash of US$51m and no debt, with a cash burn of US$36m over the trailing twelve months, giving it a cash runway of around 17 months. Analysts predict that Compugen will reach cashflow breakeven before then.
Investment
growth-positive
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
Compugen Ltd., a clinical-stage cancer immunotherapy company, has announced that it will present new clinical data on COM701 (anti-PVRIG) in triple combination with COM902 (anti-TIGIT) and pembrolizumab in microsatellite stable colorectal cancer at the American Society of Clinical Oncology (ASCO) annual meeting on May 31-June 4, 2023. The company has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. The company also has a clinical stage partnered program, rilvegostomig (previously AZD2936), a PD-1/TIGIT bispecific antibody in Phase 3 development by AstraZeneca.
CustomersPartners
growth-positive
Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
Compugen Ltd., a clinical-stage cancer immunotherapy company, has announced the publication of a peer-reviewed paper on the IL-18 pathway in cancer immunology. The company is developing COM503, an antibody approach to harness cytokine biology for cancer therapeutics, in partnership with Gilead Sciences. The paper describes how COM503 blocks the interaction between IL-18 and IL-18BP, unleashing the activity of endogenous IL-18 in the tumor. The company is planning to initiate a Phase 1 study evaluating the safety and tolerability of COM503.
InvestmentPartners
Growth-Positive
Compugen to Participate in Two Upcoming Investor Conferences
Compugen Ltd., a clinical-stage cancer immunotherapy company, has announced that its management will participate in two upcoming investor conferences in April 2024. These include the 23rd Annual Needham Virtual Healthcare Conference and the Canaccord Genuity Horizons in Oncology Virtual Conference. Compugen is known for its predictive computational discovery capabilities, which it uses to identify new drug targets and biological pathways for developing cancer immunotherapies. The company has developed two proprietary product candidates and has a clinical stage partnered program in Phase 3 development by AstraZeneca.
Investment
growth-positive
Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 31% Discount?
The intrinsic value of Compugen Ltd. is estimated to be US$3.60 per share based on a 2 Stage Free Cash Flow to Equity model, suggesting that the company is potentially 31% undervalued at its current share price of US$2.47. The valuation is based on projected future cash flows and their present value. The companys peers are currently trading at a higher discount. The valuation does not consider the possible cyclicality of an industry, or a companys future capital requirements.
Investment
growth-positive
Are You Looking for a Top Momentum Pick? Why Compugen (CGEN) is a Great Choice
Compugen (CGEN) is currently a promising momentum pick with a Momentum Style Score of A and a Zacks Rank of #2 (Buy). The companys shares have increased by 280.82% over the past quarter and year, significantly outperforming the S&P 500. The companys average 20-day trading volume is 828,535 shares. Over the past two months, 2 earnings estimates moved higher compared to 1 lower for the full year, boosting CGENs consensus estimate from -$0.33 to $0.02 in the past 60 days. Looking ahead, 3 estimates have moved upwards for the next fiscal year with no downward revisions.
Investment
growth-positive
Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
Compugen Ltd., a clinical-stage cancer immunotherapy company, has been selected to give two oral presentations at the Keystone Symposium on Cancer Immunotherapy. The event is scheduled to take place from March 17-21, 2024, in Whistler, Canada. The companys selection to present at the symposium reflects the significant discovery, research, and development taking place at Compugen. The company is working to advance its vision to transform patient lives by developing first-in-class therapeutics based on its computational target discovery platform.
CustomersPartners
growth-positive
Compugen Ltd. (NASDAQ:CGEN) Q4 2023 Earnings Call Transcript
Compugen Ltd. reported its Q4 2023 earnings, beating expectations with a reported EPS of $0.11 against expectations of $0.1. The company highlighted its preclinical licensing deal with Gilead, worth up to $848 million, including a $60 million upfront payment and a $30 million near-term milestone payment. Compugen also noted the progress of its partner, AstraZeneca, in advancing their PD-1/TIGIT bispecific into Phase III development. The company also announced management changes, with Michelle Mahler taking over as Chief Medical Officer on March 1st, 2024.
Management ChangesInvestmentPartners
growth-positive
Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced it will present data from its immuno-oncology preclinical and clinical pipeline at the American Association for Cancer Research (AACR) annual meeting in April 2024. The data includes information on novel targets discovered with Compugens computational discovery platform and a unique way to target the IL-18 binding protein pathway. The companys therapeutic pipeline includes programs aiming to address various mechanisms of immune resistance, with the most advanced program, COM503, in IND enabling studies licensed to Gilead.
CustomersPartners
Growth-Positive
Compugen Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
Compugens full year 2023 results show a significant increase in revenue, up 346% from FY 2022 to US$33.5m. The net loss has also narrowed by 44% to US$18.8m, with a loss per share of US$0.21, improved from US$0.39 loss in FY 2022. Revenue exceeded analyst estimates by 49%, however, earnings per share (EPS) fell short by 3.3%. Over the next three years, revenue is forecast to grow 23% p.a. on average, compared to an 18% growth forecast for the Biotechs industry in the US. The companys shares are down 3.8% from a week ago.
CustomersInvestment
growth-positive
Compugen Reports Fourth Quarter and Full Year 2023 Results
Compugen Ltd., a clinical-stage cancer immunotherapy company, has reported its financial results for Q4 and full year 2023, and provided a corporate update. The company made significant progress in 2023, including a license agreement with Gilead Sciences for its preclinical potential first-in-class, antibody program against IL-18 binding protein, COM503. The deal included an upfront payment of $60 million and an additional $30 million near term milestone payment. Compugen is expected to lead the Phase 1 development of COM503 and is on track for IND submission in the second half of 2024. The company also partnered with AstraZeneca to advance rilvegostomig, a PD-1/TIGIT bispecific antibody.
PartnersInvestment
growth-positive
Is a Surprise Coming for Compugen (CGEN) This Earnings Season?
Compugen Ltd. is expected to perform well in the upcoming earnings season, with analysts revising their estimates in a favorable direction. The companys current quarter estimate is at 57 cents per share, compared to a broader Zacks Consensus Estimate of 10 cents per share. This indicates that analysts have recently increased their estimates for Compugen, giving the stock a Zacks Earnings ESP of +451.63% heading into earnings season. Given that Compugen has a Zacks Rank #2 (Buy) and an ESP in positive territory, it is suggested that investors might want to consider this stock ahead of earnings.
Investment
Growth-Positive
ACM Research (ACMR) to Report Q4 Earnings: What's in Store?
ACM Research is set to report its Q4 2023 results on Feb 28, with an estimated revenue of $147.09 million, a 35.5% increase from the previous year. The companys strong market position, differentiated technology, and multi-product portfolio are expected to have contributed to this growth. However, the negative impacts of U.S.-China trade policies, changes in spending patterns of key customers, delays in shipments, and supply-chain constraints may have affected the companys top-line growth. Despite these challenges, ACM Researchs increasing investments in power devices and other trading edge devices for the EV market are expected to have boosted its revenues.
CustomersInvestment
growth-positive
Compugen to Present at the Leerink Partners Global Biopharma Conference 2024
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced that its management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference in Miami Beach, Florida, on March 11, 2024. The company is known for its predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. It has developed two proprietary product candidates and has a clinical stage partnered program with AstraZeneca.
Management Changes
growth-positive
Compugen (CGEN) is a Great Momentum Stock: Should You Buy?
Compugen (CGEN) is currently a promising momentum pick with a Momentum Style Score of B and a Zacks Rank of #2 (Buy), according to Zacks Investment Research. Over the past week, shares of Compugen have risen by 12.15%, outperforming the Zacks Medical - Biomedical and Genetics industrys 0.51% rise. Over the past quarter, shares of Compugen have risen 272.04%, and are up 220% in the last year. The companys earnings estimate has also moved higher over the past two months, increasing from -$0.34 to -$0.20.
Investment
Neutral
Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced that it will release its fourth quarter and full year 2023 financial results on March 5, 2024. The company will host a conference call and webcast to review the results and provide a corporate update. Compugen has developed two proprietary product candidates for the treatment of solid tumors and has a clinical stage partnered program with AstraZeneca. The company also has a therapeutic pipeline of early-stage immuno-oncology programs, the most advanced of which is licensed to Gilead.
Public Trading
growth-positive
Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer
Compugen Ltd., a clinical-stage cancer immunotherapy company, has announced the appointment of Michelle Mahler, M.D., as Chief Medical Officer, effective March 1, 2024. She will succeed Henry Adewoye, M.D., who is leaving Compugen to pursue other opportunities. Mahler joined Compugen in October 2023 as Vice President of Clinical Development and has been leading the preparation of the COM503 Phase 1 study, recently partnered with Gilead Sciences. She will assume overall responsibility for advancing the future development of COM701, COM902 and COM503.
Management Changes
growth-positive
Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
Compugen Ltd., a clinical-stage cancer immunotherapy company, is set to receive a $10 million milestone payment from AstraZeneca. This follows the first patient being dosed in AstraZenecas ARTEMIDE-Bil01 trial with rilvegostomig, a PD-1/TIGIT bispecific antibody derived from Compugens clinical-stage anti-TIGIT antibody, COM902. The trial is expected to recruit about 750 subjects in more than 20 countries with biliary tract cancer. The milestone payment is part of a licensing agreement between Compugen and AstraZeneca, which was established in 2018.
PartnersInvestment
Growth-Positive
Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced on January 4, 2024, that it had regained compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rule 5550(a)(2). The company had previously been notified that its ordinary shares failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days. However, the companys shares evidenced a closing bid price at or greater than the $1.00 per ordinary share minimum requirement for the last 10 consecutive business days from December 19, 2023 to January 3, 2024.
Public Trading
growth-positive
Biotech Stock Roundup: CGEN Up on GILD Deal, MRNA Gains on Study Data & More
Gilead Sciences has entered into a licensing agreement with Compugen, a clinical-stage cancer immunotherapy company. The agreement pertains to Compugens pre-clinical immunotherapy program. Gilead will make an upfront payment of $60 million to Compugen, with the potential for an additional $758 million in future development, regulatory, and commercial milestone payments. The total deal value is $848 million. Meanwhile, bluebird bio has announced the pricing of an underwritten public offering of 83.3 million shares of its common stock, expecting to generate $125 million in gross proceeds. Modernas shares gained after it announced follow-up data from a phase II study on its individualized neoantigen therapy candidate.
PartnersInvestmentManagement Changes
Growth-Positive
Compugen (NASDAQ:CGEN) delivers shareholders impressive 144% return over 1 year, surging 158% in the last week alone
Compugen Ltd.s share price has seen a significant increase of 144% in the last twelve months and 210% in the last month. However, the stock is down 85% in the last three years. Despite not currently being profitable, analysts are looking at revenue growth to gauge the growth of the underlying business. Companies without profits are expected to grow revenue every year, and at a good clip. The five-year annualised TSR loss of 3% per year compares very unfavourably with the recent share price performance.
growth-positive
Gilead (GILD), Compugen Collaborate for Immunotherapy Program
Gilead Sciences has entered into a licensing agreement with Compugen for its pre-clinical immunotherapy program. Gilead will make an upfront payment of $60 million to Compugen, with potential for additional payments up to $758 million in future development, regulatory and commercial milestone payments. The deal could total $848 million. Gilead is targeting the oncology market and aims to expand beyond the virology business. The company recently expanded its partnership with Arcellx to develop CART-ddBCMA to treat lymphomas. Gilead has also partnered with Arcus to evaluate combinations of domvanalimab plus zimberelimab and etrumadenant.
PartnersInvestment
growth-positive
Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced it will receive a $10 million milestone payment from AstraZeneca when the first patient is dosed in AstraZenecas ARTEMIDE-Bil01 trial with rilvegostomig. Rilvegostomig is a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugens clinical-stage anti-TIGIT antibody, COM902. The trial is expected to recruit about 750 subjects in more than 20 countries with biliary tract cancer. The milestone payment is part of a 2018 agreement between Compugen and AstraZeneca.
PartnersInvestment
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
Growth-Positive
Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced an exclusive license agreement with Gilead for the development and commercialization of its anti-IL-18 binding protein program, including COM503. COM503 is a pre-clinical potential first-in-class high affinity antibody targeting IL-18 binding protein with potential to treat multiple tumor types. The company will host a conference call to discuss the agreement. Compugen has developed two proprietary product candidates and has a clinical stage partnered program, rilvegostomig, in Phase 3 development by AstraZeneca.
Partners
growth-positive
Compugen shares soar on massive deal with Gilead, worth up to $848 million | CTech
Gilead Sciences has entered into an exclusive licensing agreement with Israeli company Compugen, a clinical-stage cancer immunotherapy company. Gilead will license Compugen’s potential first-in-class, pre-clinical antibody program against IL-18 binding protein, including the COM503 drug candidate. Gilead will make an upfront payment of $60 million and $30 million in a near term milestone payment to Compugen. Compugen could also receive up to an additional $758 million in future development, regulatory and commercial milestone payments, with a total deal value of $848 million.
PartnersInvestment
growth-positive
7 Promising Penny Stocks With the Potential to Defy Expectations
The article discusses seven promising penny stocks that have the potential to defy expectations. These include Aqua Metals, a company that recycles metals from spent lithium batteries; Gevo, a renewable fuels company; LiveOne, a live event streaming and ticketing platform; Eyenovia, a company that develops and markets ophthalmic micro-dose delivery technologies; Arqit Quantum, a provider of quantum encryption solutions; Compugen, a clinical-stage predictive drug discovery and development firm; and Quantum Computing, a company that aims to deliver full-stack quantum solutions. The article highlights the potential growth of these companies but also warns of the risks involved in investing in penny stocks.
Investment
growth-positive
Is Compugen (CGEN) Outperforming Other Medical Stocks This Year?
Compugen (CGEN), a member of the Medical sector, has been outperforming its peers this year, with a year-to-date return of 9.2%, compared to an average loss of 6.3% for Medical stocks. The Zacks Consensus Estimate for CGENs full-year earnings has moved 8.9% higher within the past quarter, indicating improving analyst sentiment and a positive earnings outlook trend. Another stock in the Medical sector, Evogene (EVGN), has also outperformed the sector with a year-to-date return of 4.3%.
Public Trading
growth-negative
Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?
Compugen, a loss-making company, is increasing its cash burn by 8.6% annually, which could be a concern for its shareholders. However, the companys operating revenue has also increased by 25% in the last year, indicating some business traction. As of June 2023, Compugen had a cash reserve of US$66m and no debt, with a cash runway of about 2.0 years. Analysts forecast that the company will break even in about 4 years. Given its cash burn relative to its market cap, the company may need to raise more money in the future.
Investment
growth-negative
Compugen Ltd. (NASDAQ:CGEN) Q3 2023 Earnings Call Transcript
Compugen Ltd. reported its Q3 2023 earnings, missing expectations with a reported EPS of $-0.11, compared to the expected $-0.09. The companys President and CEO, Dr. Anat Cohen-Dayag, discussed the impact of the humanitarian crisis in Israel on the companys operations and employees. Despite the challenges, the company continues to execute its plans, including ongoing proof-of-concept studies and a focus on its biomarker strategy. The company also reported progress in its partnership with AstraZeneca. The companys CFO, Alberto Sessa, reported a cash balance of approximately $57.5 million as of September 30, 2023, and an expected cash runway through at least the end of 2024.
Management ChangesCustomers
growth-positive
Compugen Reports Third Quarter 2023 Results
Compugen Ltd., a clinical-stage cancer immunotherapy company, has announced its financial results for Q3 2023 and provided a corporate update. The company has seen progress in its partnership with AstraZeneca, with the development of rilvegostomig, a PD-1/TIGIT bi-specific derived from Compugens COM902, now in Phase 3. The company has also completed patient enrollment in a proof-of-concept study for metastatic microsatellite stable colorectal cancer. Financially, the company reported a net loss of $9.9 million for Q3 2023, compared to a net loss of $11.7 million for the same period in 2022. The company expects its existing cash and cash related balances to fund its operations through the end of 2024.
Investment
growth-positive
Compugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy
Compugen Ltd., a clinical-stage cancer immunotherapy company, has announced data suggesting that its COM701 mediated anti-tumor activity in patients typically not responding to immunotherapy. The data was presented at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held on November 1-5, 2023. The results showed clinical benefit in patients with platinum resistant ovarian cancer and metastatic breast cancer. The company also presented data suggesting an association between baseline levels of the ligand for PVRIG, PVRL2, and clinical benefit, suggesting PVRL2 may be a predictive biomarker for clinical benefit in certain indications.
InvestmentPartners
Growth-Negative
Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification
Compugen Ltd., a clinical-stage cancer immunotherapy company, has received a notification from the Nasdaq Stock Market LLC stating that its ordinary shares failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The company now has a compliance period of 180 calendar days, until May 1, 2024, to regain compliance. If Compugen fails to regain compliance by the deadline, it may be eligible for an additional 180-day grace period. If it still fails to comply, its shares may be delisted from the Nasdaq Capital Market.
Public Trading
growth-positive
Compugen to Present New Data at SITC 2023 Suggesting Leading Edge of Anti-IL18 Binding Protein Antibody, COM503, in Treating Cancer
Compugen Ltd., a clinical-stage cancer immunotherapy company, has announced it will present new data on its lead pre-clinical asset COM503, a potential first-in-class anti-IL18BP antibody, at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in November 2023. The data suggest that the anti-IL18BP antibody approach has a leading edge in inhibiting tumor growth while avoiding peripheral toxicity associated with administration of a cytokine. The company plans to file the COM503 IND in 2024.
InvestmentExpand
Neutral
Compugen to Release Third Quarter 2023 Results on Tuesday, November 7, 2023
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced that it will release its third quarter 2023 financial results on November 7, 2023. The companys management will host a conference call and webcast to review the results and provide a corporate update. The update will include a discussion on Compugens data that will have been presented at the Annual Meeting of the Society for Immunotherapy of Cancer. The conference call will be available via live webcast through Compugens website, and a replay will be available on the companys website following the live webcast.
growth-positive
Compugen to Present at Single Cell Genomics 2023 Meeting
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced it will present innovative single-cell approaches and high resolution single cell spatial transcriptomics data at the Single Cell Genomics 2023 meeting. The data will highlight the computational characterization of PVRIGs expression, providing a deeper understanding of its unique biology and rationale for targeting PVRIG in tumors. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors.
CustomersPartners
growth-positive
Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of any Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer
Compugen Ltd., a clinical-stage cancer immunotherapy company, has been granted a patent by the Japanese Patent Office for treating cancer with a triple combination of any anti-PVRIG antibody with any anti-TIGIT and anti-PD-1 antibody. The patent, titled Triple Combination Antibodies Therapies, expands and protects Compugens differentiated and leading triple blockade of the DNAM-1 axis. The company is executing on a differentiated clinical strategy to evaluate the benefit of their chemotherapy-free, triple immunotherapy combination of COM701, COM902, and pembrolizumab to treat patients with cancer.
Customers
Compugen to Present New Clinical and Pre-Clinical Data in Multiple Presentations at SITC 2023
growth-positive
Is Aspira Women's Health (AWH) Stock Outpacing Its Medical Peers This Year?
Aspira (AWH), a member of the Medical group, is currently outperforming its peers in the sector. The companys year-to-date performance shows a gain of about 22.9%, while the Medical sector has lost an average of 3.9%. The Zacks Consensus Estimate for AWHs full-year earnings has moved 3.2% higher, indicating improved analyst sentiment and a stronger earnings outlook. Aspira currently has a Zacks Rank of #2 (Buy). Another Medical stock, Compugen (CGEN), has also outperformed the sector with a year-to-date return of 46.7%.
Investment
growth-positive
Compugen to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced that management will present virtually at the H.C. Wainwright 25th Annual Global Investment Conference. The presentation will be available on demand on the companys website. Compugen is a therapeutic discovery and development company utilizing computational discovery capabilities to identify new drug targets and pathways for cancer immunotherapies. The company has developed two proprietary product candidates and has a clinical stage partnered program. Compugens shares are listed on Nasdaq and the Tel Aviv Stock Exchange.
Public Trading
growth-positive
Has Compugen (CGEN) Outpaced Other Medical Stocks This Year?
Compugen, a company in the Medical group, is outperforming its peers in terms of stock performance. It currently has a Zacks Rank of #2 (Buy) and its earnings outlook is improving. The companys year-to-date returns have increased by 62.1%, while the Medical group has lost about 3.2% on average. Compugen belongs to the Medical - Biomedical and Genetics industry, which has lost an average of 12% so far this year. The article also mentions another outperforming stock in the Medical sector, Corcept Therapeutics, which has a year-to-date return of 58.6%. Investors interested in Medical stocks should continue to track Compugen and Corcept Therapeutics.
Customers
growth-positive
Compugen Ltd. (NASDAQ:CGEN) Q2 2023 Earnings Call Transcript
Compugen Ltd. held its Q2 2023 earnings call on August 7, 2023. The company discussed its ongoing clinical trials and research efforts, particularly in the field of cancer treatment. Compugen is developing novel drug targets and potential first-in-class drugs, with a focus on chemotherapy-free triple cancer immunotherapy combinations. The company also highlighted its recent patent win with the European Patent Office, which upheld broad claims in Compugens PVRIG patent. Looking ahead, Compugen plans to report initial findings from ongoing proof-of-concept studies by the end of the year, with final data expected in 2024.
Management ChangesInvestment
growth-positive
Compugen Reports Second Quarter 2023 Results
Compugen Ltd., a clinical-stage cancer immunotherapy company, has announced its financial results for Q2 2023 and provided a corporate update. The company is advancing enrollment in two proof-of-concept studies evaluating triple blockade of DNAM-1 axis in patients with microsatellite stable colorectal cancer and platinum resistant ovarian cancer. Initial findings are expected by the end of the year. The company also plans to present new data from multiple studies by the end of the year. Compugens partner, AstraZeneca, continues to advance the development of rilvegostomig in multiple trials. As of June 30, 2023, the companys cash, cash equivalents and cash investments were approximately $66.5 million.
CustomersPartnersManagement Changes
Growth-Positive
Compugen to Release Second Quarter 2023 Results on Monday, August 7, 2023
Compugen Ltd., a clinical-stage cancer immunotherapy company, has announced that it will release its second quarter financial results on August 7, 2023. The company will host a conference call and webcast to review the results and provide a corporate update. Compugen is a therapeutic discovery and development company that uses predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. The company has developed two proprietary product candidates and has a clinical stage partnered program with AstraZeneca.
Public Trading
growth-positive
Compugen Wins on PVRIG European Patent Opposition Pursued by GSK and a Third Party
Compugen Ltd., a clinical-stage cancer immunotherapy company, has announced that the broad claims of its Anti-PVRIG Antibodies for use in treating cancer patent granted by the European Patent Office have been successfully maintained. The patent was opposed by GSK and an anonymous opponent represented by a third party. The decision supports Compugens patent strategy in novel target discovery. The company is currently leading the way in evaluating the triple blockade of PVRIG in combination with TIGIT and PD-1 in two proof of concept studies in tumors typically not responsive to immunotherapy.
Customers
growth-positive
Compugen Doses First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizumab Platinum Resistant Ovarian Cancer Proof-of-Concept Study
Compugen Ltd. has announced the dosing of the first patient in a triple immunotherapy combination proof-of-concept study for platinum resistant ovarian cancer. The study will evaluate the combination of COM701, Compugens anti-PVRIG antibody, with COM902, Compugens anti-TIGIT antibody, and pembrolizumab. The goal of the study is to build on previous data and better understand the contribution of the components. Initial findings are expected by the end of 2023. The study aims to provide new treatment options for patients with platinum resistant ovarian cancer, addressing a significant unmet need. Compugen is a clinical-stage cancer immunotherapy company focused on computational target discovery.
Customers
growth-positive
Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement
Compugen Ltd. has regained compliance with the minimum bid price requirement set forth by Nasdaq. The company received a notification letter from the Listing Qualifications Department of Nasdaq, confirming that its ordinary shares had a closing bid price at or greater than $1.00 for the last 10 consecutive business days. Compugen is a clinical-stage cancer immunotherapy company that utilizes computational target discovery. It has developed two proprietary product candidates and has a clinical stage partnered program. The companys shares are listed on Nasdaq and the Tel Aviv Stock Exchange.
Public Trading
growth-positive
Compugen's COM701 (anti-PVRIG) Demonstrates Preliminary Durable Anti-Tumor Activity in Triple Immunotherapy Combination in Patients with Recurrent Metastatic MSS Endometrial Cancer
Compugen Ltd. announced data showing that its COM701 in combination with nivolumab and BMS-986207 demonstrated preliminary signal of durable anti-tumor activity in patients with recurrent, metastatic MSS endometrial cancer. The treatment showed a favorable safety profile and an association between greater peripheral immune activation and clinical benefit. The data supports the potential of COM701 in hard-to-treat tumors. The companys Chief Medical Officer expressed excitement about the preliminary data and the potential of the triple immunotherapy combination. The abstract is published on the ASCO virtual platform and the poster will be available on the companys website.
CustomersPartners
growth-negative
We Think Compugen (NASDAQ:CGEN) Needs To Drive Business Growth Carefully
The article discusses Compugens cash burn and its impact on the company. It analyzes the companys cash reserves and cash runway, indicating that Compugen has about 2.1 years to develop its business. The article also mentions that Compugen is increasing its cash burn, but revenue is growing at the same time. It raises the question of how easily Compugen can raise more money if needed, considering its cash burn relative to its market capitalization. While the cash burn is not a major concern, shareholders should consider the potential cost of raising more money in the future. The article concludes by mentioning that Compugen has warning signs that investors should be aware of.
Investment
growth-negative
Cathie Wood is Selling These 12 Stocks in 2023
Cathie Woods ARK Investment Management has been selling stocks in 2023, resulting in portfolio losses. The net portfolio worth of ARK Innovation ETF fell from $13 billion in March 2022 to $7.4 billion in March 2023. Wood reduced the holdings of ARK Innovation ETF from 50 stocks to 28 stocks. Despite the losses, ARK remains optimistic about the future, stating that the adoption of new technologies accelerates during tumultuous times. However, ARK has been experiencing investor outflows, with all ARK ETFs except ARK Innovation Fund seeing outflows in 2023. The article also lists 12 stocks that Cathie Wood sold or reduced her positions in, including Organovo Holdings, Magic Software Enterprises, Compugen, Niu Technologies, Atai Life Sciences, Fate Therapeutics, and NIO Inc.
Investment
growth-positive
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?
ANI Pharmaceuticals has outperformed the Medical sector in terms of stock performance. It currently has a Zacks Rank of #1 (Strong Buy) and its earnings outlook is improving. The company has gained about 10.6% year-to-date, while the Medical sector has returned an average of -2%. Another Medical stock, Compugen, has also outperformed the sector with a 7.5% gain. ANI Pharmaceuticals is part of the Medical - Biomedical and Genetics industry, which has lost an average of 6.7% so far this year. Investors are advised to track ANI Pharmaceuticals and Compugen for their solid performance.
InvestmentCustomers
growth-positive
Compugen Reports First Quarter 2023 Results
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced its financial results for the first quarter of 2023. The company reported a cash balance of $74.3 million, which is expected to support its operations and milestones until at least the end of 2024. Compugen is focused on its unique triple combination immuno-oncology approach, which has shown preliminary clinical benefit in two tumor types. The company is conducting proof-of-concept studies and expects to report initial findings by the end of the year. Additionally, Compugen presented new pre-clinical data on its lead asset, COM503, at a recent conference. The company believes that its differentiated assets have the potential to transform the lives of cancer patients. Compugens shares are listed on Nasdaq and the Tel Aviv Stock Exchange.
Investment
growth-positive
Compugen to Host DNAM-1 Axis Virtual Investor Event with KOL Drew Pardoll on Tuesday, May 23, 2023
Compugen Ltd. will host a virtual DNAM-1 Axis Investor Event to discuss the potential of simultaneous blockade of PVRIG, TIGIT, and PD-1 in enhancing anti-tumor immune responses. The event will feature Drew Pardoll, Chairman of Compugens Scientific Advisory Board, who will provide a mechanistic rationale for Compugens differentiated DNAM-1 axis hypothesis. The company is a clinical-stage cancer immunotherapy company focused on computational target discovery. Compugen has developed two proprietary product candidates and has a clinical stage partnered program. The event aims to attract investors and showcase the companys potential in cancer immunotherapy.
Investment
Compugen to Present at the JMP Securities Life Sciences Conference
growth-positive
Compugen to Release First Quarter 2023 Results on Monday, May 15, 2023
Compugen Ltd., a clinical-stage cancer immunotherapy company, will release its first quarter 2023 financial results and host a conference call and webcast to review the results and provide a corporate update. Compugen utilizes computational target discovery to identify new drug targets and biological pathways for developing cancer immunotherapies. The company has developed two proprietary product candidates and has a clinical stage partnered program. Compugens therapeutic pipeline consists of programs aiming to address various mechanisms of immune resistance. The company is headquartered in Israel and its shares are listed on Nasdaq and the Tel Aviv Stock Exchange.
Public Trading
growth-positive
Compugen to Present New Clinical Data Showing Preliminary Anti-Tumor Activity of COM701 Triple Combination in Recurrent MSS-Metastatic Endometrial Cancer at ASCO 2023
Compugen Ltd. will present new clinical data on COM701 in triple combination with BMS-986207 and nivolumab in metastatic endometrial cancer at the ASCO annual meeting. Compugen is a clinical-stage cancer immunotherapy company that utilizes computational target discovery. They have developed two proprietary product candidates and have a clinical stage partnered program. Compugens shares are listed on Nasdaq and the Tel Aviv Stock Exchange.
PartnersCustomers
growth-positive
Compugen to Present Data on its Lead Pre-Clinical Asset COM503 in an Oral Presentation at the 20th CIMT Annual Meeting
Compugen plans to file an IND for its lead pre-clinical asset COM503 in 2024. The company will present pre-clinical data on COM503, a potential first-in-class anti-IL18 binding protein antibody, at the 20th CIMT annual meeting. The data shows that COM503 binds with high affinity to IL-18 binding protein, freeing IL-18 and restoring NK and T cell activity. This approach presents a unique opportunity to use a blocking antibody to release IL-18 at the site where it is needed to fight cancer. Compugen is a clinical-stage cancer immunotherapy company utilizing computational target discovery.
InvestmentExpand
growth-positive
Compugen to Present New Research Enabling Accurate Detection and Study of Novel Target PVRIG at AACR 2023
Compugen Ltd. will present new research at the AACR annual meeting, demonstrating the accurate detection and study of the novel target PVRIG following the correction of the GENCODE gene model. This advancement could lead to the development of new cancer immunotherapies. Compugen is a clinical-stage cancer immunotherapy company focused on computational target discovery. The company has developed two proprietary product candidates, COM701 and COM902, and has a clinical stage partnered program, rilvegostomig. The research findings will be presented in a poster session at the AACR annual meeting on April 18, 2023.
Customers
Is Certara (CERT) Outperforming Other Medical Stocks This Year?
Compugen (NASDAQ:CGEN investor three-year losses grow to 90% as the stock sheds US$11m this past week
growth-positive
Compugen Ltd. (NASDAQ:CGEN) Q4 2022 Earnings Call Transcript
Compugen Ltd. held its Q4 2022 earnings call, discussing its financial results and progress in clinical trials. The company reported a net loss of $3.1 million for Q4 2022 and $33.7 million for the year. However, it also highlighted significant progress in its clinical trials, particularly in the treatment of microsatellite stable colorectal cancer and platinum-resistant ovarian cancer. Compugen also announced the termination of its collaboration with Bristol Myers Squibb to focus on these two indications. The company also mentioned its partnership with AstraZeneca, which could potentially earn it up to $200 million in milestones.
PartnersInvestment
growth-positive
Compugen to Participate in a Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference
Compugen Ltd., a clinical-stage cancer immunotherapy company, will participate in a fireside chat at the Oppenheimer 33rd Annual Healthcare Conference. The company utilizes computational target discovery to develop cancer immunotherapies. Compugen has two proprietary product candidates and a clinical stage partnered program. They are headquartered in Israel and listed on Nasdaq and the Tel Aviv Stock Exchange.
Management Changes
growth-positive
Compugen Doses First Patient in Triple Combination COM701, COM902 and Pembrolizumab MSS CRC Proof-of-Concept Study
Compugen Ltd. has announced the initiation of a proof-of-concept study evaluating the triple combination of COM701, COM902, and pembrolizumab in patients with metastatic microsatellite stable colorectal cancer (MSS CRC). The study aims to build on previous data and identify patients most likely to respond to the treatment. The first patient has been dosed, and initial findings are expected by the end of 2023. The study addresses the limited treatment options for patients with MSS CRC and liver metastases. Compugen is a clinical-stage cancer immunotherapy company focused on computational target discovery. They have developed two proprietary product candidates, COM701 and COM902, and have a therapeutic pipeline of early-stage immuno-oncology programs.
CustomersPartners
Why Compugen Shares Are Up Today
growth-positive
Compugen Reports Fourth Quarter and Full Year 2022 Results
Compugen Ltd., a clinical-stage cancer immunotherapy company, reported its financial results for Q4 and the full year 2022. The company made significant progress in 2022, including presenting encouraging data from sixty patients in tumor types typically not responding to immunotherapy. Compugen reported $7.5 million in revenue for Q4 and for the year ended December 31, 2022. The company had approximately $83.7 million in cash, cash equivalents, restricted cash and short-term bank deposits as of December 31, 2022. Compugen expects that its current cash will be sufficient to fund its operating plans at least through the end of 2024.
Investment
growth-positive
Rilvegostomig, AstraZeneca's Bi-specific Antibody Derived from Compugen's COM902, Expected to Progress into Phase 3
Compugens bi-specific antibody, rilvegostomig, derived from COM902, is expected to progress into Phase 3 this year. AstraZeneca plans to initiate a Phase 3 trial for rilvegostomig and is also developing an expanded Phase 2 program. The expansion of the rilvegostomig clinical program demonstrates the commitment to explore the potential of TIGIT and COM902. The companys license agreement with AstraZeneca allows for the development of bi-specific and multi-specific antibody products. Compugen has received an upfront payment of $10 million and additional milestone payments of $15.5 million, with the potential to receive up to $200 million in milestones for the first product. The date of the event described in the article is not provided.
Expand
growth-negative
Compugen changes drug discovery business strategy - News Bit
Compugen Ltd., a predictive drug discovery company, has experienced both positive and negative growth throughout its history. Despite not generating any revenue in its 30 years of existence, the company is still seen as having potential. Recently, Compugen announced a change in focus and ended its collaboration agreement with Bristol Myers Squibb. The company has shifted its business model multiple times, from providing computer services to developing its own drugs. It has made significant progress in the field of immunotherapy, particularly in the area of immune checkpoint inhibitors. However, the TIGIT sector, in which Compugen operates, has fallen out of fashion after a trial failure by Roche. Compugen has $100 million in funding and is now looking to promote its products independently. The company faces risks but hopes to have more control over its products and their development.
PartnersInvestment
growth-positive
Compugen Expands anti-PVRIG COM701 Intellectual Property Portfolio
Compugen Ltd. has been granted a new patent by the European Patent Office for anti-PVRIG antibodies for use in cancer treatment. The patent expands and protects the use of COM701, a potential first-in-class anti-PVRIG antibody, for treating cancer patients. COM701 activates T cells and/or NK cells and competes with other antibodies for specific binding to PVRIG. The patent also covers the use of anti-PVRIG antibodies in combination with antagonistic antibodies targeting additional immune checkpoints. The patent is expected to expire no earlier than February 2036. Compugen is a clinical-stage cancer immunotherapy company that utilizes computational target discovery.
Partners
growth-negative
לא רק חיסכון בהוצאות: קומפיוג'ן מסיימת את ההסכם עם BMS
Israeli biopharmaceutical company Compugen has announced a strategic focus process, which resulted in a 5.8% drop in its NASDAQ stock value, bringing the companys worth to $126 million. This represents a 92% crash from its peak in August 2020. The company has also terminated its joint development agreement with pharmaceutical corporation Bristol Myers Squibb (BMS), which was signed in 2018. As part of the agreement, Compugens drug COM701 was to be tested in a clinical trial alongside two BMS products. BMS had invested $32 million in Compugen as part of the agreement.
PartnersLayoffs
growth-positive
Compugen's Computational Discovery Leverages Single Cell Spatial Transcriptomics to Gain In-Depth Understanding of the Tumor Microenvironment
Compugen Ltd. announced that it will give a presentation on exploring the immune-tumor microenvironment using high resolution single-cell spatial transcriptomics. The presentation will take place at the Keystone Symposium: Cancer Immunotherapy: Decoding the Cancer Immunity Interactome. Compugens computational platform is being used to identify new drug targets and biological pathways for developing cancer immunotherapies. The companys ability to study cancer at the spatially resolved single-cell level is expanding its understanding of the complex interactions in the tumor microenvironment and opening the door to new therapeutic approaches.
PartnersExpand
growth-positive
Bristol Myers Squibb invests $20m in Compugen cancer drug
Bristol Myers Squibb has completed a $20 million investment in Compugen Ltd. to collaborate on the development of a novel immune checkpoint that prevents cancers from attacking the immune system. The investment is being made at a 33% premium over the previous days closing price.
Investment
growth-positive
Compugen Doses First Patient in Phase 1 Combination Study of COM902 and COM701 in Patients with Advanced Malignancies
Compugen Ltd. has announced the dosing of the first patient in its Phase 1 clinical study evaluating the combination of COM902 and COM701 in patients with advanced malignancies. The study aims to assess the safety, tolerability, and preliminary antitumor activity of the combination therapy. Compugen believes that the dual blockade of the DNAM axis members PVRIG and TIGIT has the potential to expand the number of patients who respond to immunotherapy. The company is also conducting single, dual, and triple combination clinical studies and expects initial results of the COM902 monotherapy dose escalation study in Q4 2021. The Phase 1 study is being conducted in multiple oncology clinical centers in the United States with an estimated enrollment of 90 participants across all arms.
PartnersExpand
growth-positive
Compugen Presents Research Supporting PVRIG as a Novel and Differentiated Checkpoint in the DNAM-1 Axis
Compugen Ltd. announced the presentation of research supporting the differentiation of PVRIG from other immune checkpoint inhibitors. The research suggests that PVRIG may be an important checkpoint involved in T-cell expansion and could enhance T cell proliferation and infiltration into tumors. The findings indicate that targeting the PVRIG pathway has the potential to provide new treatment options for both inflamed and less inflamed tumors. The research was presented at the Society for Immunotherapy of Cancer (SITC) 2021 Targets for Cancer Immunotherapy seminar. Compugen is a clinical-stage cancer immunotherapy company.
CustomersPartners
Growth-Negative
"2021 תהיה שנה חשובה ומרובת אבני דרך עבור קומפיוגן"
Compugen, a dual-listed company specializing in cancer immunotherapy, reported a net loss of approximately $9.9 million for Q1 2021. The companys research and development expenses stood at about $7.3 million, compared to approximately $4.7 million in the same period last year. The increase is primarily due to expenses related to drug manufacturing and clinical activity. The companys cash, cash equivalents, and short and long-term deposits amounted to approximately $119.4 million at the end of Q1 2021, compared to approximately $124.4 million at the end of 2020. The company has no debt.
Investment
growth-positive
Compugen Announces Expansion of Research Collaboration with Johns Hopkins University for a Novel Myeloid Target Discovered by Compugen
Compugen has expanded its research collaboration with Johns Hopkins University to investigate a novel myeloid target. The collaboration aims to explore the biological function and mechanism of the target, which has shown potential as a myeloid immunomodulator. The research program will evaluate and validate the role of the target in various tumors. Compugen sees its early-stage programs as a pipeline growth engine and hopes that the studies will provide a strong biological foundation for the development of a new therapeutic program. The collaboration with Johns Hopkins has been instrumental in the development of Compugens clinical stage asset, COM701. Compugen is a clinical-stage cancer immunotherapy company based in Israel.
PartnersExpand
growth-positive
Compugen Expands Clinical Collaboration Agreement with Bristol Myers Squibb with Phase 1b Combination Study of COM701 with Opdivo®
Compugen Ltd. has announced the expansion of its clinical collaboration agreement with Bristol Myers Squibb. Under the amended agreement, Bristol Myers Squibb will supply Opdivo® (nivolumab) for Compugens Phase 1b cohort expansion study. The study aims to assess COM701, Compugens anti-PVRIG antibody, in combination with Opdivo® in selected cancer indications. The study is expected to begin in the second quarter of 2021. Compugen is excited to evaluate COM701 in three settings and believes it will enhance their leadership position in the DNAM-1 axis space. Bristol Myers Squibb continues to be a valued partner for Compugens clinical program. The amendment allows Bristol Myers Squibb to supply Opdivo® to the study. The study will enroll patients with ovarian, breast, endometrial, and microsatellite-stable colorectal cancers.
PartnersExpand
Compugen Announces First Development Milestone in License Agreement with AstraZeneca for the Development of Bispecific and Multi-specific Antibody P...
growth-positive
Compugen Announces Addition of Immuno-oncology Pioneer Dr. Nils Lonberg to its Scientific Advisory Board
Compugen Ltd. has announced the addition of Dr. Nils Lonberg to its Scientific Advisory Board (SAB). Dr. Lonberg is a pioneer in the field of immuno-oncology and has more than 30 years of experience in the biopharmaceutical industry. This addition is expected to contribute to Compugens vision and work in extending the reach of immunotherapies to more patients. Dr. Lonbergs expertise will help in identifying new immunotherapy targets and advancing candidates through the clinic. The company expressed gratitude to Dr. Charles Drake, who will be stepping down from the SAB. Compugen is a clinical-stage therapeutic discovery and development company focused on cancer immunotherapy. Their lead product candidate, COM701, is undergoing a Phase 1 clinical study.
Partners
growth-positive
Compugen Doses First Patient in Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® and Anti-TIGIT Antibody
Compugen announced the dosing of the first patient in a Phase 1/2 study evaluating the triple combination of COM701 with Bristol Myers Squibbs PD-1 immune checkpoint inhibitor, Opdivo, and their investigational anti-TIGIT antibody. The study aims to evaluate the simultaneous blockade of three immune checkpoint pathways and accelerate the clinical evaluation of Compugens DNAM axis hypothesis. The company believes that targeting PVRIG simultaneously with TIGIT and PD-1 blockers has the potential to expand cancer immunotherapy treatment options. Compugen is partnering with Bristol Myers Squibb for this study.
Partners
growth-positive
Compugen Expands Patent Portfolio for TIGIT Inhibitor COM902 with New US Composition of Matter Patent
Compugen Ltd. has been granted a new patent by the United States Patent and Trademark Office (USPTO) for its immuno-oncology therapeutic antibody targeting TIGIT. The patent expands intellectual property protection for COM902, a high affinity, fully human antibody that blocks the interaction of TIGIT with its ligand, PVR. COM902 is currently being evaluated in a Phase 1 clinical trial for the treatment of advanced malignancies. The patent is expected to expire no earlier than August 2037 in the United States. This patent adds to the existing patents for COM902 in the United States and Europe. Compugen is a clinical-stage therapeutic discovery and development company focused on cancer immunotherapy.
Investment
growth-positive
Compugen Announces FDA Clearance of IND Application for Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® (Nivolumab) and TIGIT Inhibitor
Compugen has received clearance from the FDA for its Phase 1/2 study evaluating the triple combination of its anti-PVRIG antibody, Opdivo, and BMS-986207 in patients with advanced solid tumors. The study aims to evaluate the simultaneous blockade of three immune checkpoint pathways and accelerate the clinical evaluation of Compugens DNAM axis hypothesis. The company plans to initiate the study in the second half of 2020. Compugen is a clinical-stage cancer immunotherapy company focused on predictive target discovery.
PartnersInvestment
growth-positive
Compugen makes equity offering
Compugen Ltd. is embarking on an equity offering, with an expected gross proceeds of approximately $75 million. The companys share price has risen sharply recently due to positive initial results of a cancer treatment trial and expansion of its collaboration agreement with Bristol-Myers Squibb. The offering is expected to close on or about March 16, 2020. SVB Leerink and Stifel are acting as joint bookrunning managers for the offering.
Investment
growth-positive
Compugen Announces Updated Clinical Data from Ongoing COM701 Phase 1 Study
Compugen Ltd., a clinical-stage cancer immunotherapy company, reported updated data from its Phase 1 dose escalation study of COM701. The data showed encouraging signals of preliminary antitumor activity in patients with advanced solid tumors who have exhausted all available standard therapies. COM701 is a first-in-class investigational therapeutic antibody targeting PVRIG, a novel immune checkpoint discovered by Compugen. The company plans to present the full data at a future scientific conference. The updated data demonstrated the well-tolerated nature of COM701 and its potential to enhance anti-tumor immune response. Compugen is focused on the development of novel drug targets and therapeutics in the field of cancer immunotherapy.
Customers
growth-positive
Compugen Announces Phase 1/2 Triple Combination Study to Evaluate COM701 in Combination With Bristol-Myers Squibb's Opdivo® (Nivolumab) and TIGIT Inhibitor
Compugen plans to initiate a Phase 1/2 study to evaluate a triple combination of its anti-PVRIG antibody, Opdivo, and BMS-986207 in advanced solid tumors. The study aims to accelerate the clinical evaluation of Compugens science-driven DNAM axis hypothesis. The company will be the study sponsor, with Opdivo and BMS-986207 supplied by Bristol-Myers Squibb. The triple combination study is expected to begin in the second half of 2020, pending FDA clearance. Compugen is excited to expand its collaboration with Bristol-Myers Squibb and test the hypothesis that the triple combination will enable robust activation of T cells and anti-tumor immune responses in non-responsive or refractory cancer patients.
Partners
growth-positive
Compugen expands agreement with BMS
Israeli drug discovery company Compugen is conducting three cancer treatment trials this year, two of them with Bristol-Myers Squibb. Compugen has expanded its cooperation agreement with Bristol-Myers Squibb to test its COM701 anti-cancer drug in combination with another Bristol-Myers Squibb drug. Compugens share price has risen 160% this year. The company aims to discover more targets in the body for activating the immune system and is conducting trials for its own drugs as well as in combination with Bristol-Myers Squibbs drugs. Compugen also has an agreement with Bayer for a new immunotherapy track. The company reduced its staff earlier this year.
PartnersExpand
growth-positive
Compugen Announces New U.S. Patent for Methods of Screening for Anti-PVRIG Antibodies
Compugen Ltd. has been granted a new patent by the United States Patent and Trademark Office (USPTO) for methods of screening for anti-PVRIG antibodies. The patent covers a method of screening for any anti-PVRIG antibody that inhibits the binding of PVRIG with PVRL2. The patent is expected to expire in the United States no earlier than February 2036. COM701, a humanized antibody developed by Compugen, has shown promising results in enhancing T cell activation and inhibiting tumor growth. It is currently in Phase 1 clinical trials for the treatment of advanced solid tumors. Compugen is a clinical-stage therapeutic discovery and development company focused on cancer immunotherapy.
Investment
growth-positive
Compugen Further Expands Intellectual Property Portfolio With New European Patent for Anti-PVRIG Antibodies
Compugen Ltd., a clinical-stage cancer immunotherapy company, has been granted a new patent by The European Patent Office (EPO) for the use of any anti-PVRIG antibody in the treatment of cancer. The patent, EPO Patent No. 3258951, relates to any anti-PVRIG antibody that activates T cells and/or NK cells for use in cancer treatment. The patent also covers these antibodies for use in combination with other immunostimulatory antibody, a cytokine therapy, or an immunomodulatory drug for cancer treatment. The patent is expected to expire in Europe no earlier than February 2036.
Investment
growth-positive
Compugen Announces Appointment of Dr. Oliver Froescheis as Senior Vice President, Corporate and Business Development
Compugen Ltd. has announced the appointment of Oliver Froescheis, Ph.D., as Senior Vice President, Corporate and Business Development. This appointment is expected to have a growth-positive impact on the company. Dr. Froescheis will oversee the companys business development strategy and execution. Compugen aims to expand its innovative immuno-oncology pipeline and pursue additional collaboration opportunities. Dr. Froescheis brings over 20 years of experience in the pharmaceutical industry, with expertise in research, project management, marketing, and business development. Compugen is a clinical-stage cancer immunotherapy company that utilizes computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy.
Management Changes
growth-positive
Compugen Added to the NASDAQ Biotechnology Index
Compugen Ltd. has been selected for addition to the NASDAQ Biotechnology Index. The addition will become effective on December 23, 2019. The NASDAQ Biotechnology Index tracks the performance of securities listed on the NASDAQ Stock Market that are classified as either Biotechnology or Pharmaceuticals. Compugen is a clinical-stage cancer immunotherapy company that utilizes predictive target discovery to develop therapeutics in the field of cancer immunotherapy. The companys business model involves entering into collaborations for its novel targets and drug product candidates. Compugens shares are listed on Nasdaq and the Tel Aviv Stock Exchange.
Public Trading
Compugen Expands Patent Portfolio for COM902 with New Composition of Matter and Use Patent in Europe
growth-positive
https://www.jpost.com/HEALTH-SCIENCE/Israeli-team-develops-novel-therapy-to-target-advanced-cancerous-tumors-606918
Compugen, a cancer immunotherapy company, has disclosed positive preliminary results from its Phase 1 clinical trial for an antibody acting against a novel cancer drug target. The trial demonstrated initial signals of anti-tumor activity in patients with advanced solid tumors. Compugen also announced pre-clinical data for another therapeutic antibody targeting TIGIT. The company has received FDA clearance for its investigational new drug application for COM902 and plans to initiate a Phase 1 clinical trial in early 2020. Compugen has collaborations with Bristol-Myers Squibb and Bayer. The company aims to bring its therapeutic pipeline to market through collaborations with large multinational pharma and biotech companies.
CustomersPartnersInvestment
growth-positive
Compugen Announces FDA Clearance of IND Application for COM902
Compugen Ltd., a clinical-stage cancer immunotherapy company, has received clearance from the U.S. Food and Drug Administration for its investigational new drug (IND) application for COM902, an immuno-oncology therapeutic antibody targeting TIGIT in patients with advanced malignancies. The company plans to initiate a Phase 1 clinical trial in early 2020 to evaluate the safety, tolerability, and preliminary anti-tumor activity of COM902. Compugen is the only company with clinical candidates targeting both PVRIG and TIGIT, giving it a differentiated position in the immuno-oncology space. The company has made significant progress in recent years and has three anticipated Phase 1 programs in the clinic expected in 2020. These programs address targets discovered through Compugens computational discovery platform.
InvestmentExpand
growth-positive
Compugen Expands Intellectual Property Portfolio for COM701 with New U.S. Patent Covering Combination Use with anti-PD-1 Antibody
Compugen Ltd. has been granted a new patent by the United States Patent and Trademark Office. The patent covers the use of COM701, a therapeutic antibody, in combination with anti-PD-1 antibodies for cancer immunotherapy treatment. This patent expands and protects the use of COM701 for activating T cells in cancer patients. COM701 is a humanized antibody that binds to PVRIG, a novel immune checkpoint target. The company is also conducting Phase 1 clinical trials for COM701 in combination therapy with a PD-1 inhibitor. The patent is expected to expire no earlier than February 2036 in the United States.
PartnersInvestment
growth-positive
Compugen Appoints Eran Perry to Its Board of Directors
Compugen Ltd. has announced the appointment of Mr. Eran Perry to its board of directors, effective July 1, 2019. The company also announced the retirement of Yair Aharonowitz, Ph.D. and Arie Ovadia, Ph.D. from its board of directors. Mr. Perry brings over 20 years of experience in the healthcare industry and will contribute to the support and guidance of the management team. Compugen is a clinical-stage cancer immunotherapy company focused on predictive target discovery. The appointment of Mr. Perry is expected to enhance the companys long-term strategic objectives and shareholder value.
Management Changes
growth-positive
Compugen Doses First Patient in COM701/Opdivo® (Nivolumab) Combination Arm of Phase 1 Study in Patients With Advanced Solid Tumors
Compugen has dosed the first patient in the combination arm of its Phase 1 study, combining escalating doses of COM701 with a fixed dose of Opdivo in patients with advanced solid tumors. The company has successfully progressed through the COM701 monotherapy dose escalation arm and is now initiating the combination study. The Phase 1 study aims to assess the safety and tolerability of administering escalating doses of COM701 monotherapy and combination administration with Opdivo in patients with advanced solid tumors. Compugen has entered into a clinical trial collaboration with Bristol-Myers Squibb for the evaluation of the combination of COM701 and Opdivo in patients with advanced solid tumors. Bristol-Myers Squibb has also made a strategic $12 million investment in Compugen.
PartnersInvestment
growth-positive
Compugen Announces Issuance of Two U.S. Composition of Matter Patents for COM701, Its Lead Immuno-Oncology Product Candidate
Compugen Ltd. has been granted two composition of matter patents for its lead immuno-oncology therapeutic antibody candidate, COM701. The patents expand Compugens intellectual property protection for COM701 and cover exclusivity in the United States for any purpose. The patents are part of Compugens IP strategy to support the commercialization plans of its pipeline programs. COM701 is a humanized antibody that blocks the interaction of PVRIG, a novel immune checkpoint target, with its ligand, PVRL2. It has shown potential in enhancing T cell activation and generating anti-tumor immune responses. COM701 is currently in Phase 1 clinical trials for advanced solid tumors. Compugen is a clinical-stage therapeutic discovery and development company based in Israel.
PartnersInvestment
growth-positive
Compugen reports revenue, announces restructuring
Cancer drug discovery company Compugen reported $17.8 million in revenue for 2018, compared to zero in 2017, thanks to agreements with AstraZeneca and Bayer. The company also announced a corporate restructuring plan to reduce costs by consolidating and streamlining R&D operations. As part of the plan, Compugen will consolidate R&D activities in Israel, reduce its workforce by 35%, and outsource certain pre-clinical activities. The company expects savings of up to $10 million annually. Despite posting a net loss for the fourth quarter of 2018 and the year as a whole, Compugen ended 2018 with $45.7 million in cash and expects its cash runway to extend through mid-2020. The restructuring is aimed at focusing resources on the companys immuno-oncology programs and long-term core value drivers.
Layoffs
growth-positive
Compugen Announces Publication of Two Peer-Reviewed Papers Demonstrating the Role of PVRIG as a Novel Immune Checkpoint for Cancer Immunotherapy
Compugen Ltd., a clinical-stage cancer immunotherapy company, has announced the publication of preclinical data demonstrating the potential of its inhibitory antibody targeting PVRIG, called COM701, as an effective cancer immunotherapy. The findings were published in two peer-reviewed papers. The data supports Compugens clinical development plan for COM701 and its expectation that targeting the PVRIG pathway will expand treatment options for cancer patients. Compugens Phase 1 study of COM701 in patients with advanced solid tumors is ongoing, and the company recently announced a clinical collaboration with Bristol-Myers Squibb. The papers also highlight the potential of COM701 in combination with anti-TIGIT antibodies and PD-1 inhibitors. Compugen is a therapeutic discovery and development company focused on cancer immunotherapy.
PartnersInvestment
growth-positive
Compugen's Phase 1 Trial of COM701 Featured as a Trial-in-Progress at The ASCO-SITC Clinical Immuno-Oncology Symposium
Compugen Ltd. announced that its Phase 1 clinical trial evaluating COM701 will be featured in a trial-in-progress poster at The ASCO-SITC Clinical Immuno-Oncology Symposium. The poster will be presented by Drew W. Rasco, M.D and will provide updated enrollment information. Compugen is a clinical-stage cancer immunotherapy company focused on predictive target discovery.
PartnersInvestment
growth-positive
BMS invests $12m in Compugen for tumor collaboration
Compugen Ltd. and Bristol Myers Squibb have entered into a clinical trial collaboration to evaluate Compugen’s COM701 with BMSs PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. Bristol-Myers Squibb will invest $12 million in Compugen through a share purchase agreement. Compugen will sponsor the ongoing Phase 1 trial, evaluating the combination of COM701 and Opdivo in four tumor types. The collaboration gives Compugen access to Opdivo, potentially accelerating the timeline for clinical testing of COM701 in other combinations. The investment is expected to close on or about October 12, 2018.
Investment
growth-positive
Compugen earns $7.8m payment from Bayer
Compugen Ltd. has earned a $7.8 million milestone payment from Bayer AG for its cancer drug BAY 1905254. The drug targets the ILDR2 protein and has entered Phase I clinical trials. The development of this drug is a major boost for Compugens ability to identify new mechanisms for cancer treatments using its big data systems. Compugens share price has increased by 4.3% on the TASE, giving the company a market cap of NIS 829 million.
Investment
growth-positive
Compugen signs cancer drug licensing deal worth up to $200m
Compugen Ltd. has entered into an exclusive license agreement with MedImmune, the R&D arm of AstraZeneca, for the development of bi-specific and multi-specific immuno-oncology antibody products. Compugen will receive a $10 million upfront payment and is eligible for up to $200 million in milestones and royalties. The agreement allows Compugen to monetize scientific advances in its programs while continuing to advance its lead programs into clinical trials. MedImmune aims to generate novel immunotherapy targets to improve the lives of cancer patients. The agreement is expected to have a positive impact on Compugens growth.
PartnersInvestment
growth-positive
Compugen to Present at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Next Month
Compugen Ltd. announced that CGEN-15032, a novel myeloid and epithelial immuno-oncology target, will be presented at a cancer immunotherapy conference. CGEN-15032 belongs to a portfolio of novel targets discovered by the company. The companys therapeutic pipeline consists of immuno-oncology programs against novel drug targets it has discovered. Compugen is a therapeutic discovery and development company in the field of cancer immunotherapy.
PartnersInvestment
growth-positive
Compugen reports positive cancer therapy results
Compugen Ltd. announced positive initial experimental results for the first two of five in silico predicted targets for antibody drug conjugate (ADC) cancer therapy. The two candidates demonstrate low expression levels in normal critical tissues and higher expression in multiple cancer types. Compugen said that these results suggest that the two target candidates may serve for the development of ADC therapy in oncology. Initial validation of the remaining three candidates, and further testing of these two, is ongoing. Compugen plans to commence a therapeutic antibody discovery program against a selected ADC target later this year.
Expand
growth-positive
Publications - Compugen
The article discusses the preliminary antitumor activity of the combination of COM701, BMS-986207, and nivolumab in patients with recurrent, metastatic MSS endometrial cancer. The study was presented at the ASCO annual meeting. Compugen, the company behind the research, is focused on developing cancer immunotherapy drugs targeting the PVRIG and TIGIT pathways. The article highlights the potential of these pathways and their relevance in cancer treatment. The key issues discussed in the article are related to partners and customers. However, specific partners or customers are not mentioned. The date of the event described in the article is June 2-6, 2023. The confidence level of the answer is 8.
PartnersCustomers
Compugen Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 113 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 10 classification IDs that could be used for matching.
Compugen Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 91/100 |
| Missing | markets, not claimed |
| BI Verification | Sharon Shapira |
| Registrar ID | 511779639 |
| Crunchbase | compugen |
| Creator | Jenny Sotnik-Talisman |
| Creator email | genys30@yahoo.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-07-27T00:00:00.000Z |
| Created | 2014-07-01T00:00:00.000Z |
| Status detail | Public on NASDAQ on Aug, 2000;Public on TASE on Jan, 2002; |